Details of Disease

General Information of Disease (ID: DIS30POX)

• Disease Name: Small lymphocytic lymphoma
• Synonyms: small lymphocytic lymphoma; leukemia, chronic LYMPHOCYTIC; leukemia, lymphocytic, chronic; leukemia, chronic lymphatic; B-cell CLL; B cell chronic lymphocytic leukemia; B-cell chronic lymphoid leukemia; B cell chronic lymphocytic leukaemia; lymphoplasmacytic leukaemia; chronic lymphocytic leukaemia; B cell lymphocytic leukemia; B-cell chronic lymphocytic leukemia; hematopoeitic - chronic lymphocytic leukaemia (CLL); B-cell lymphocytic leukaemia; lymphoplasmacytic leukemia; B cell lymphocytic leukaemia; chronic lymphogenous leukaemia; Chronic Lymphocytic Leukemia; B-cell chronic lymphogenous leukaemia; BCLL; chronic lymphatic leukaemia; chronic lymphocytic leukaemia (CLL); B-cell chronic lymphoid leukaemia; hematopoeitic - chronic lymphocytic leukemia (CLL); B cell CLL; chronic B-cell lymphocytic leukemia; CLL; chronic lymphocytic leukemia; chronic lymphocytic leukemia (CLL); chronic B-cell lymphocytic leukaemia; chronic lymphatic leukemia; B-cell chronic lymphogenous leukemia; B-CLL; chronic lymphogenous leukemia; B-cell lymphocytic leukemia
• Disease Class: 2A82: Mature B-cell leukaemia
• Definition: B-cell chronic lymphocytic leukemia (B-CLL) is a type of B-cell non-Hodgkin lymphoma, and the most common form of leukemia in Western countries, affecting elderly adults (mean age of 67 and 72 years) with a slight male predominance (1.7:1), and characterized by a highly variable clinical presentation that can include asymptomatic disease or non-specific B-symptoms such as unintentional weight loss, severe fatigue, fever (without evidence of infection), and night sweats as well as cervical lymphadenopathy, splenomegaly and frequent infections. Some patients can also develop autoimmune complications such as autoimmune hemolytic anemia or immune thrombocytopenia. The clinical course is extremely heterogeneous with survival ranging from a few months to several decades.
• Disease Hierarchy:
  DIS0C4XI: Chronic leukemia
  DISPW4EO: Indolent B-cell non-Hodgkin lymphoma
  DIS87TGM: Acute lymphoblastic leukaemia
  DISKAXO0: Neoplasm of mature B-cells
  DIS30POX: Small lymphocytic lymphoma
• ICD Code:
  ICD-11: ICD-11: 2A82.0
  ICD-10: ICD-10: C83.0, C91.1
  Expand ICD-10: C81,C82,C83,C84,C85,C86,C91,C92,C93,C94,C95,C91
  Expand ICD-9: 202.8,204.0,204.1,204.1V10.60,208.9
• Disease Identifiers:
  MONDO ID: MONDO_0004948
  MESH ID: D015451
  UMLS CUI: C0023434
  OMIM ID: 151400
  MedGen ID: 44120
  HPO ID: HP:0005550
  Orphanet ID: 67038
  SNOMED CT ID: 51092000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 12 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Chlorambucil	DMRKE63	Approved	Small molecular drug	[1]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[2]
Idelalisib	DM602WT	Approved	Small molecular drug	[3]
IPI-145	DMWA24P	Approved	Small molecular drug	[4]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[5]
Obinutuzumab	DM3BVAE	Approved	Antibody	[6]
Ofatumumab	DM295PR	Approved	Antibody	[7]
Pirtobrutinib	DMRG1X3	Approved	Small molecular drug	[8]
Prednisone	DM2HG4X	Approved	Small molecular drug	[9]
Rituximab	DM1YVZT	Approved	Antibody	[10]
Uracil mustard	DMHL7OB	Approved	Small molecular drug	[11]
Zanubrutinib	DMJWRQP	Approved	NA	[12]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ICP-022	DMU72KL	Phase 3	Small molecular drug	[13]
ISF35	DMBZK3P	Phase 2	NA	[14]
APG-2575	DMPWBM2	Phase 1/2	Small molecular drug	[15]
IOV-2001	DMRWHJT	Phase 1/2	Cell therapy	[16]
PBCAR20A	DM7NKWQ	Phase 1/2	CAR T Cell Therapy	[17]
MS-553	DM7ER9J	Phase 1	NA	[18]
YTB323	DM5BMIO	Phase 1	CAR T Cell Therapy	[19]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 269 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BMP1	TT0L58T	Limited	Biomarker	[20]
BMP2K	TT32VXH	Limited	Biomarker	[21]
BUB1	TT78309	Limited	Altered Expression	[22]
CASP2	TT12VNG	Limited	Biomarker	[23]
CD33	TTJVYO3	Limited	Biomarker	[24]
CDK8	TTBJR4L	Limited	Altered Expression	[25]
CSPG4	TT7MYXI	Limited	Biomarker	[26]
EZH1	TTNJA0C	Limited	Biomarker	[27]
F2RL3	TTD0652	Limited	Altered Expression	[28]
GPR183	TTME5YJ	Limited	Altered Expression	[29]
GRB2	TTEYRJ9	Limited	Biomarker	[30]
HDAC10	TTYHPU6	Limited	Altered Expression	[31]
HDAC7	TTMUEK1	Limited	Altered Expression	[32]
IDUA	TT0IUKX	Limited	Biomarker	[33]
IL15RA	TTGN89I	Limited	Altered Expression	[34]
IL3RA	TTENHJ0	Limited	Biomarker	[24]
KCNK3	TTGR91N	Limited	Biomarker	[35]
KDM4A	TTZHPB8	Limited	Altered Expression	[36]
KLK14	TTDA81R	Limited	Biomarker	[37]
KMT5B	TTJGV7F	Limited	Biomarker	[38]
KMT5C	TT7H3YM	Limited	Biomarker	[38]
MAP3K11	TTETX6Q	Limited	Biomarker	[39]
MAS1	TTOISYB	Limited	Biomarker	[40]
MCM7	TT1RM3F	Limited	Biomarker	[41]
MELK	TTBZOTY	Limited	Biomarker	[42]
MPL	TTIHYA4	Limited	Biomarker	[43]
NTSR2	TT31Q0V	Limited	Biomarker	[44]
PRCP	TTTJZ4M	Limited	Biomarker	[20]
ROR2	TTUDPCI	Limited	Altered Expression	[45]
SLAMF6	TTSIYJ6	Limited	Biomarker	[46]
SLC22A6	TTTYH7A	Limited	Biomarker	[35]
SMYD2	TT7YJFO	Limited	Altered Expression	[47]
SPN	TTOZAX0	Limited	Biomarker	[48]
SUV39H1	TTUWQTK	Limited	Biomarker	[38]
TIGIT	TTWNL74	Limited	Altered Expression	[49]
TPP1	TTOVYPT	Limited	Genetic Variation	[50]
TRB	TT84HCW	Limited	Genetic Variation	[51]
TTK	TTP7EGM	Limited	Biomarker	[33]
XPO1	TTCJUR4	Limited	Biomarker	[52]
ZNF224	TT1CDXL	Limited	Biomarker	[53]
HLA-DQA1	TTU2I3J	Disputed	Genetic Variation	[54]
TNFSF13	TTOI1RM	Disputed	Genetic Variation	[55]
ABL1	TT6B75U	moderate	Biomarker	[56]
ADCYAP1R1	TT5OREU	moderate	Biomarker	[57]
ANGPT2	TTKLQTJ	moderate	Altered Expression	[58]
BCL11A	TTR61MW	moderate	Biomarker	[59]
BCL2L2	TTQ79W8	moderate	Biomarker	[60]
CASP6	TTKW4ML	moderate	Genetic Variation	[61]
CCR8	TTE836A	moderate	Biomarker	[62]
CD3G	TTV3XPL	moderate	Altered Expression	[63]
CDC7	TTSMTDI	moderate	Biomarker	[64]
CRLF2	TTRMZ0N	moderate	Biomarker	[65]
CSF2RA	TT6MP2Z	moderate	Altered Expression	[66]
CTPS1	TTN12BZ	moderate	Biomarker	[67]
CXCR5	TTIW59R	moderate	Biomarker	[68]
CYSLTR1	TTGKOY9	moderate	Altered Expression	[69]
CYSLTR2	TT0PZR5	moderate	Altered Expression	[69]
DPP7	TTOYT5L	moderate	Biomarker	[70]
DPP9	TTNDUL7	moderate	Biomarker	[71]
EPHB6	TTZEMUY	moderate	Biomarker	[72]
GPRC6A	TTI1PRE	moderate	Biomarker	[69]
HLA-G	TTLKFB3	moderate	Altered Expression	[73]
HOXA13	TTN26OM	moderate	Biomarker	[74]
IFNGR2	TT13TL0	moderate	Genetic Variation	[75]
IL12A	TTRTK6Y	moderate	Genetic Variation	[75]
ITPR1	TT5HWAT	moderate	Biomarker	[76]
ITPR3	TTH1769	moderate	Biomarker	[76]
KIR2DS1	TTVWAGF	moderate	Biomarker	[77]
KLKB1	TTN0PCX	moderate	Biomarker	[78]
KLRG1	TT299E6	moderate	Biomarker	[79]
LONP1	TTM1VPZ	moderate	Biomarker	[80]
MRGPRX1	TTIX6PK	moderate	Biomarker	[69]
OXER1	TT7WBSV	moderate	Biomarker	[69]
PDE4A	TTZ97H5	moderate	Genetic Variation	[81]
PLK2	TT976FS	moderate	Altered Expression	[82]
PNP	TTMCF1Y	moderate	Altered Expression	[83]
PREP	TTNGKET	moderate	Altered Expression	[71]
S1PR2	TTVSMOH	moderate	Altered Expression	[84]
SLC22A8	TTTQR47	moderate	Altered Expression	[85]
TNFRSF14	TTWGTC1	moderate	Biomarker	[86]
TNFRSF18	TTG6LA7	moderate	Altered Expression	[87]
TNFRSF25	TTDV6BQ	moderate	Biomarker	[88]
TRIP10	TTKHTGE	moderate	Biomarker	[89]
VDAC1	TTAMKGB	moderate	Altered Expression	[90]
ABCB4	TTJUXV6	Strong	Altered Expression	[91]
ABCC1	TTOI92F	Strong	Genetic Variation	[92]
ANPEP	TTPHMWB	Strong	Biomarker	[93]
ANXA5	TT2Z83I	Strong	Biomarker	[94]
B2M	TTY7FKA	Strong	Altered Expression	[95]
BAK1	TTFM7V0	Strong	Biomarker	[33]
BCL2A1	TTGT9C7	Strong	Biomarker	[96]
BIRC2	TTQ5LRD	Strong	Biomarker	[97]
BIRC3	TTAIWZN	Strong	Genetic Variation	[98]
BLK	TTNDSC3	Strong	Altered Expression	[99]
BTG1	TTL7N2W	Strong	Biomarker	[100]
BTLA	TTER58P	Strong	Genetic Variation	[101]
CASP10	TTX5HEK	Strong	Genetic Variation	[102]
CASP9	TTB6T7O	Strong	Biomarker	[103]
CCL21	TTLZK1U	Strong	Biomarker	[104]
CCL3	TT8I4WB	Strong	Biomarker	[105]
CCR6	TTFDB30	Strong	Biomarker	[106]
CD14	TT6I7DC	Strong	Biomarker	[107]
CD160	TTOFEAS	Strong	Biomarker	[108]
CD2	TTJDUNO	Strong	Altered Expression	[109]
CD22	TTM6QSK	Strong	Biomarker	[110]
CD27	TTDO1MV	Strong	Biomarker	[111]
CD28	TTQ13FT	Strong	Biomarker	[112]
CD37	TTFCW29	Strong	Altered Expression	[113]
CD5	TTEGYK1	Strong	Biomarker	[114]
CD58	TT5KSBY	Strong	Altered Expression	[115]
CD6	TTMF6KC	Strong	Genetic Variation	[116]
CD69	TTPQE9F	Strong	Biomarker	[117]
CD70	TTNCIE0	Strong	Altered Expression	[118]
CD74	TTCMYP9	Strong	Biomarker	[119]
CD80	TT89Z17	Strong	Biomarker	[120]
CD83	TTT9MRQ	Strong	Altered Expression	[121]
CD86	TT53XHB	Strong	Altered Expression	[122]
CDC37	TT5SOEU	Strong	Biomarker	[123]
CDK9	TT1LVF2	Strong	Altered Expression	[124]
CFLAR	TTJZQYH	Strong	Genetic Variation	[125]
CLEC12A	TT70N8V	Strong	Biomarker	[126]
CR1	TTEA8OW	Strong	Biomarker	[127]
CR2	TT0HUN7	Strong	Altered Expression	[128]
CRY1	TT5MLZR	Strong	Altered Expression	[129]
CSNK1D	TTH30UI	Strong	Biomarker	[130]
CTSG	TTQAJF1	Strong	Genetic Variation	[131]
CXCL13	TT0NIZ1	Strong	Biomarker	[132]
CXCR3	TT1UCIJ	Strong	Biomarker	[133]
CYP3A4	TTWP7HQ	Strong	Biomarker	[134]
DBH	TTYIP79	Strong	Biomarker	[135]
DCK	TTJOCE4	Strong	Biomarker	[136]
DEK	TT1NMGV	Strong	Biomarker	[137]
DUSP5	TTZN92A	Strong	Altered Expression	[138]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[139]
ENTPD1	TTYM8DJ	Strong	Altered Expression	[140]
FBXW7	TT29KY7	Strong	Biomarker	[141]
FCGR1A	TTZK4I3	Strong	Biomarker	[142]
FCGR2B	TT5RWKQ	Strong	Biomarker	[143]
FMNL1	TTW20PQ	Strong	Altered Expression	[144]
FOXP1	TT0MUCI	Strong	Altered Expression	[145]
GAL	TTXZAJ5	Strong	Biomarker	[146]
GALNS	TTT9YPO	Strong	Biomarker	[147]
GRM3	TT8A9EF	Strong	Biomarker	[148]
HDAC1	TT6R7JZ	Strong	Altered Expression	[149]
HDC	TTV9GOF	Strong	Altered Expression	[150]
HSF1	TTN6STZ	Strong	Biomarker	[151]
ICOS	TTE5VP6	Strong	Genetic Variation	[152]
IKZF2	TTKT5NV	Strong	Biomarker	[153]
IKZF3	TTCZVFZ	Strong	Biomarker	[154]
IL11RA	TTZPLJS	Strong	Altered Expression	[155]
IL12RB2	TT4SWR8	Strong	Biomarker	[156]
IL15	TTJFA35	Strong	Biomarker	[157]
IL18RAP	TTZUJVE	Strong	Altered Expression	[158]
IL19	TT87RWS	Strong	Biomarker	[114]
IL1RL1	TT4GZA4	Strong	Genetic Variation	[159]
IL21R	TTZO9B0	Strong	Biomarker	[160]
IL24	TT1EPXZ	Strong	Biomarker	[161]
IL2RB	TT9721Y	Strong	Altered Expression	[34]
IL4R	TTDWHC3	Strong	Biomarker	[162]
IL6	TTT1V78	Strong	Biomarker	[163]
IL7	TT8FRMO	Strong	Biomarker	[164]
IL9	TT0JTFD	Strong	Altered Expression	[165]
IRAK4	TTILUKB	Strong	Biomarker	[166]
IRF8	TTHUBNK	Strong	Genetic Variation	[167]
ITCH	TT5SEWD	Strong	Biomarker	[168]
ITGAL	TT48WR6	Strong	Biomarker	[169]
ITGB1	TTBVIQC	Strong	Biomarker	[170]
ITGB2	TTIJWR7	Strong	Biomarker	[169]
JAK3	TTT7PJU	Strong	Biomarker	[171]
LAG3	TTNVXAW	Strong	Biomarker	[172]
LAMP1	TTC214J	Strong	Genetic Variation	[173]
LCK	TT860QF	Strong	Altered Expression	[99]
LGALS1	TTO3NYT	Strong	Biomarker	[146]
LILRA4	TT7WTBR	Strong	Biomarker	[114]
LILRB2	TTHC6XU	Strong	Altered Expression	[174]
LILRB4	TTREOKA	Strong	Biomarker	[175]
LTB	TTHQ6US	Strong	Altered Expression	[176]
LYN	TT1RWNJ	Strong	Altered Expression	[99]
MAGEA1	TT63M7Q	Strong	Biomarker	[177]
MAP2K1	TTIDAPM	Strong	Altered Expression	[178]
MBL2	TTMQDZ5	Strong	Genetic Variation	[179]
MBTPS1	TTNSM2I	Strong	Biomarker	[180]
MKI67	TTB4UNG	Strong	Altered Expression	[181]
MTDH	TTH6SA5	Strong	Altered Expression	[182]
MTHFR	TTQWOU1	Strong	Genetic Variation	[183]
MYC	TTNQ5ZP	Strong	Altered Expression	[184]
MYH2	TTBIL13	Strong	Biomarker	[185]
NCK1	TTMA3VF	Strong	Genetic Variation	[186]
NOTCH2	TT82FVD	Strong	Altered Expression	[187]
NPM1	TTHBS98	Strong	Biomarker	[188]
NR0B2	TT25A9Q	Strong	Altered Expression	[189]
NRAS	TTW2R9X	Strong	Genetic Variation	[190]
ORAI1	TTE76YK	Strong	Biomarker	[191]
PAWR	TT3I4WV	Strong	Biomarker	[192]
PAX5	TTA4REJ	Strong	Genetic Variation	[193]
PDCD1	TTNBFWK	Strong	Biomarker	[194]
PDE1B	TT3ZS42	Strong	Biomarker	[195]
PDE3B	TTN34SQ	Strong	Altered Expression	[196]
PDE4B	TTVIAT9	Strong	Biomarker	[197]
PDE7A	TT1BC3A	Strong	Biomarker	[198]
PDE7B	TTWIEY9	Strong	Biomarker	[196]
PIM1	TTTN5QW	Strong	Altered Expression	[199]
PIM2	TT69J2Z	Strong	Altered Expression	[200]
PMEL	TT8MK59	Strong	Biomarker	[201]
POLB	TTA0XPV	Strong	Biomarker	[114]
PRAME	TTPH7T0	Strong	Genetic Variation	[202]
PRKCB	TTYPXQF	Strong	Genetic Variation	[203]
PSMB6	TT8EPLT	Strong	Genetic Variation	[204]
PTGS2	TTVKILB	Strong	Altered Expression	[205]
PTP4A2	TT1MHKD	Strong	Altered Expression	[206]
PTPN6	TT369M5	Strong	Altered Expression	[189]
PTPRC	TTUS45N	Strong	Genetic Variation	[61]
QPCT	TTJ7YTV	Strong	Genetic Variation	[207]
REL	TT1ZCTH	Strong	Biomarker	[208]
S1PR1	TT9JZCK	Strong	Altered Expression	[209]
SCT	TTOBVIN	Strong	Biomarker	[210]
SELL	TT2IYXF	Strong	Biomarker	[211]
SEMA4D	TT5UT28	Strong	Biomarker	[212]
SFRP4	TTX8I1Y	Strong	Biomarker	[213]
SLC22A2	TT0XOJN	Strong	Altered Expression	[214]
SLC23A2	TTOP832	Strong	Biomarker	[215]
SMYD3	TTKLJYX	Strong	Biomarker	[216]
SSTR2	TTZ6T9E	Strong	Altered Expression	[217]
STAT6	TTWOE1T	Strong	Posttranslational Modification	[218]
SYVN1	TT8XKYM	Strong	Genetic Variation	[219]
TCF3	TTULOD8	Strong	Altered Expression	[214]
TFRC	TT8MG4S	Strong	Altered Expression	[220]
TK1	TTP3QRF	Strong	Altered Expression	[221]
TLR7	TTRJ1K4	Strong	Biomarker	[222]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[223]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[224]
TNFRSF13B	TTL9OD4	Strong	Altered Expression	[225]
TNFRSF13C	TT7NJSE	Strong	Genetic Variation	[226]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[227]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[112]
TNFSF10	TTA5MS9	Strong	Biomarker	[228]
TNFSF11	TT9E8HR	Strong	Biomarker	[229]
TNFSF14	TTKVENM	Strong	Biomarker	[230]
TNFSF4	TTBW580	Strong	Biomarker	[231]
TRPC1	TTA76X0	Strong	Biomarker	[232]
TSPAN7	TTMT6VE	Strong	Altered Expression	[233]
USP7	TTXU3EQ	Strong	Biomarker	[234]
VDR	TTK59TV	Strong	Biomarker	[235]
WNT5A	TTKG7F8	Strong	Altered Expression	[236]
XIAP	TTK3WBU	Strong	Altered Expression	[237]
ATR	TT8ZYBQ	Definitive	Biomarker	[238]
CASR	TTBUYHA	Definitive	Biomarker	[239]
CCR7	TT2GIDQ	Definitive	Biomarker	[240]
CD200	TT0BE68	Definitive	Biomarker	[241]
CD274	TT8ZLTI	Definitive	Biomarker	[194]
CD34	TTZAVYN	Definitive	Altered Expression	[242]
CD52	TTQT5S9	Definitive	Biomarker	[243]
FCER2	TTCH6MU	Definitive	Biomarker	[244]
HSP90AA1	TT78R5H	Definitive	Altered Expression	[99]
IL21	TT9QEJ6	Definitive	Biomarker	[245]
IL22	TTLDX4N	Definitive	Biomarker	[245]
IL4	TTLGTKB	Definitive	Altered Expression	[218]
JAK2	TTRMX3V	Definitive	Biomarker	[189]
MCL1	TTL53M6	Definitive	Biomarker	[33]
MS4A1	TTUE541	Definitive	Biomarker	[243]
MYD88	TTB6Q2O	Definitive	Genetic Variation	[166]
NR1I3	TTRANFM	Definitive	Biomarker	[239]
OPRM1	TTKWM86	Definitive	Genetic Variation	[125]
PIK3CB	TT9H4P3	Definitive	Biomarker	[246]
PRKAR1A	TTNAHEX	Definitive	Biomarker	[239]
ROR1	TTDEJAU	Definitive	Biomarker	[236]
RPS6KB1	TTG0U4H	Definitive	Genetic Variation	[102]
TLR9	TTSHG0T	Definitive	Biomarker	[247]
TNFSF13B	TTWMIDN	Definitive	Biomarker	[248]

This Disease Is Related to 7 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC7A9	DTP7AEQ	Limited	Biomarker	[249]
ABCB5	DTKVEXO	Strong	Altered Expression	[250]
ABCC11	DTWN7FC	Strong	Biomarker	[251]
SLC28A1	DT0EQPW	Strong	Biomarker	[252]
SLC28A3	DT4YL5R	Strong	Altered Expression	[253]
SLC29A2	DTW78DQ	Strong	Altered Expression	[254]
SLC35B2	DT81RKJ	Strong	Biomarker	[255]

This Disease Is Related to 11 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP3A7	DERD86B	Limited	Biomarker	[256]
HK1	DEDMAGE	Limited	Genetic Variation	[257]
NAT1	DE7OAB3	Limited	Genetic Variation	[258]
PCYT1A	DEQYXD4	Limited	Biomarker	[33]
PGPEP1	DEVDR46	Limited	Biomarker	[20]
AKR1C4	DEAJN47	moderate	Biomarker	[259]
PGM3	DER0EN5	moderate	Biomarker	[67]
SI	DE5EO4Y	moderate	Biomarker	[260]
ACP3	DEDW5H6	Strong	Biomarker	[261]
SULT1E1	DESTKG6	Strong	Biomarker	[262]
UGT2B17	DEAZDL8	Strong	Altered Expression	[263]

This Disease Is Related to 451 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACOXL	OTW680HT	Limited	Genetic Variation	[125]
ADCY10	OTYSTB0R	Limited	Biomarker	[33]
AKAP12	OTCVRDDX	Limited	Biomarker	[264]
ARHGEF1	OTXU4HBW	Limited	Biomarker	[265]
ARSH	OTG0X9UQ	Limited	Biomarker	[30]
ATP2B4	OTMWFDAC	Limited	Biomarker	[266]
BLNK	OTSSPF6F	Limited	Biomarker	[267]
BTG2	OTZF6K1H	Limited	Biomarker	[100]
CACYBP	OTJMZD2T	Limited	Altered Expression	[268]
CBFB	OTIAC6W4	Limited	Biomarker	[269]
CCDC34	OTZ3AGSQ	Limited	Altered Expression	[270]
CEP55	OTGSG2PA	Limited	Biomarker	[33]
CLEC17A	OTZWM3JI	Limited	Altered Expression	[266]
DDX39A	OT0Z6E1K	Limited	Biomarker	[249]
DDX39B	OTEVCFVU	Limited	Biomarker	[249]
DKC1	OTX7DJR6	Limited	Biomarker	[271]
DOCK10	OTI3MBLV	Limited	Altered Expression	[272]
DOCK2	OTZTS3PA	Limited	Biomarker	[273]
DOHH	OTDRAT3F	Limited	Genetic Variation	[274]
DTX1	OTYX91DX	Limited	Altered Expression	[175]
DUSP22	OTEZ3U85	Limited	Genetic Variation	[275]
EGR2	OTAVQ78J	Limited	Genetic Variation	[276]
FARP2	OTNRQIMK	Limited	Genetic Variation	[277]
FCRLA	OT6MK4M1	Limited	Genetic Variation	[278]
FLT3LG	OTU0YGC4	Limited	Altered Expression	[279]
GAR1	OTA580RX	Limited	Biomarker	[280]
GOLGA6A	OTHU9MRX	Limited	Altered Expression	[281]
GPLD1	OTUUQOVY	Limited	Biomarker	[282]
GPS2	OT065FSS	Limited	Genetic Variation	[283]
H1-0	OTRLJK4Z	Limited	Altered Expression	[284]
HNRNPL	OT0DJX74	Limited	Altered Expression	[22]
IFI16	OT4SPU0U	Limited	Altered Expression	[285]
ING4	OT0VVG4V	Limited	Biomarker	[286]
ING5	OTRNNSFM	Limited	Biomarker	[286]
INPPL1	OTCDAVBQ	Limited	Biomarker	[287]
KANK2	OT3SZIWM	Limited	Altered Expression	[268]
KCNRG	OTXHYFOD	Limited	Biomarker	[288]
KLF6	OTQY9S7F	Limited	Altered Expression	[289]
KLHL6	OTLDECOX	Limited	Genetic Variation	[290]
LAX1	OT2ARFAV	Limited	Altered Expression	[266]
LMNB1	OT100T3P	Limited	Altered Expression	[291]
LPIN1	OTQ75KF2	Limited	Biomarker	[292]
MAD2L1	OTXNGZCG	Limited	Biomarker	[33]
MAPK8IP2	OTDUHLN0	Limited	Biomarker	[293]
MARCHF1	OTI2EYO6	Limited	Biomarker	[294]
MCC	OTQVI1EM	Limited	Genetic Variation	[295]
MED19	OTT9RT5N	Limited	Genetic Variation	[296]
MEF2D	OT7CEIG0	Limited	Altered Expression	[297]
MLLT1	OT41UZU5	Limited	Genetic Variation	[26]
MPEG1	OT7DAO0F	Limited	Biomarker	[33]
MTSS1	OT5DTDO2	Limited	Altered Expression	[298]
MYT1	OTC3660I	Limited	Biomarker	[33]
NCR3	OT20M764	Limited	Altered Expression	[299]
NDUFAB1	OTF906UR	Limited	Biomarker	[300]
NOP10	OT1MVO2F	Limited	Biomarker	[280]
NRK	OTGR01FF	Limited	Biomarker	[35]
PDCD6	OT2YA5M8	Limited	Genetic Variation	[301]
PHB2	OTCAX3AW	Limited	Genetic Variation	[302]
PIAS3	OT3TWH9R	Limited	Biomarker	[303]
PIGR	OT6GLSUL	Limited	Biomarker	[266]
PLAGL1	OTZAO900	Limited	Genetic Variation	[304]
PMAIP1	OTXEE550	Limited	Biomarker	[305]
PRKD2	OTIFSVI8	Limited	Genetic Variation	[306]
PWWP3A	OTXQVL4U	Limited	Altered Expression	[307]
RABGEF1	OTWC3Z3R	Limited	Biomarker	[308]
RAC2	OTAOHFNH	Limited	Genetic Variation	[309]
RAD21	OTQS84ZF	Limited	Biomarker	[310]
RAD52	OT0OTDHI	Limited	Genetic Variation	[311]
RAD54L	OTEGMAKG	Limited	Genetic Variation	[311]
RASGRP2	OTABVLVQ	Limited	Biomarker	[308]
RBM14	OTO9GMBD	Limited	Altered Expression	[268]
RPL11	OT3VZ6OE	Limited	Biomarker	[312]
RPS27	OTFXKY7P	Limited	Biomarker	[33]
SENP2	OTPQJXIR	Limited	Biomarker	[313]
SHISA3	OTE8TPCP	Limited	Altered Expression	[314]
SIGIRR	OTNC3XFD	Limited	Altered Expression	[315]
SIGLEC6	OTO4F5C9	Limited	Altered Expression	[316]
SIL1	OTDI85I5	Limited	Genetic Variation	[302]
SP140	OTQZHFMT	Limited	Genetic Variation	[125]
SRF	OTW18FQN	Limited	Biomarker	[317]
STN1	OT8UWRA3	Limited	Biomarker	[318]
SUGP1	OT7W0EB8	Limited	Genetic Variation	[319]
SUV39H2	OTU0F4LL	Limited	Altered Expression	[38]
TAP2	OTWSYFI7	Limited	Genetic Variation	[320]
TINF2	OT861N2N	Limited	Genetic Variation	[321]
TJP1	OTBDCUPK	Limited	Biomarker	[322]
TMCC3	OTAIQ6V6	Limited	Biomarker	[266]
TNR	OTVJGAFN	Limited	Genetic Variation	[323]
TP53INP1	OT2363Z9	Limited	Altered Expression	[268]
TRIP13	OTFM3TI9	Limited	Biomarker	[324]
TSACC	OT3QW6PH	Limited	Altered Expression	[268]
ACTA2	OTEDLG8E	Disputed	Genetic Variation	[167]
CLPTM1L	OTDJWQXI	Disputed	Genetic Variation	[167]
CSRNP1	OTDK1FPH	Disputed	Genetic Variation	[207]
FKRP	OTMUZ7GH	Disputed	Genetic Variation	[325]
HLA-DQA2	OT1DH0N9	Disputed	Genetic Variation	[54]
IPCEF1	OTOUIHID	Disputed	Genetic Variation	[167]
MYNN	OT61R1HP	Disputed	Genetic Variation	[167]
PPIL3	OT0GPU73	Disputed	Genetic Variation	[277]
RFX7	OTKFNW3A	Disputed	Genetic Variation	[167]
TSBP1	OT5GE8IO	Disputed	Genetic Variation	[167]
AATF	OT1QOKLD	moderate	Altered Expression	[326]
ACP1	OTJ9CKLU	moderate	Biomarker	[327]
ADAM28	OT3GBVHL	moderate	Biomarker	[328]
ALLC	OTZE4XV7	moderate	Biomarker	[329]
AMFR	OTQRX7LC	moderate	Altered Expression	[330]
ANP32B	OT3SQMLU	moderate	Altered Expression	[162]
ANXA7	OTLMD0TK	moderate	Biomarker	[331]
APCDD1	OTV9AD0L	moderate	Altered Expression	[332]
ARNT	OTMSIEZY	moderate	Genetic Variation	[333]
ARSD	OTAHW9M8	moderate	Altered Expression	[334]
ASXL1	OTX931AW	moderate	Genetic Variation	[335]
B4GALNT1	OTCY80HS	moderate	Biomarker	[336]
BAG6	OT4Z0S2U	moderate	Biomarker	[337]
BCOR	OTG013AX	moderate	Biomarker	[338]
BFAR	OTTBG0V7	moderate	Biomarker	[89]
BMF	OT90NSLI	moderate	Genetic Variation	[186]
BST1	OTAV5SE7	moderate	Biomarker	[339]
CBFA2T2	OTNOIB23	moderate	Genetic Variation	[340]
CCDC50	OTSE1YM5	moderate	Biomarker	[341]
CCL13	OTNX0JD0	moderate	Biomarker	[62]
CDKN2B	OTAG24N1	moderate	Biomarker	[213]
CLCN5	OT9YXZSO	moderate	Genetic Variation	[342]
CNOT1	OTTEU05F	moderate	Genetic Variation	[343]
COG1	OT3JSAF7	moderate	Biomarker	[344]
CRB3	OTQKPTMU	moderate	Biomarker	[345]
CRYGC	OTYSTQWI	moderate	Biomarker	[346]
CYFIP2	OTCAY35T	moderate	Biomarker	[74]
DDX46	OTB2X9TO	moderate	Altered Expression	[90]
DMRT2	OTA39QNR	moderate	Genetic Variation	[347]
DOCK11	OTFSTN6A	moderate	Biomarker	[348]
DPF3	OTEWLMNB	moderate	Biomarker	[349]
DSC3	OTYG47F8	moderate	Biomarker	[350]
DUSP2	OTH54FMR	moderate	Biomarker	[57]
DVL1	OTD67RF1	moderate	Biomarker	[351]
DVL2	OTMNYNCM	moderate	Altered Expression	[351]
E2F7	OTWW358N	moderate	Biomarker	[352]
EBF1	OTZ61YYH	moderate	Altered Expression	[111]
EFNA4	OTITKZQH	moderate	Biomarker	[72]
EIF4G1	OT2CF1E6	moderate	Posttranslational Modification	[353]
ETV3	OTEN03BM	moderate	Biomarker	[354]
FBLIM1	OTFHXMON	moderate	Biomarker	[355]
FLII	OT7G9JG6	moderate	Biomarker	[356]
FOXD3	OTXYV6GO	moderate	Altered Expression	[357]
FZD6	OTBCPII8	moderate	Altered Expression	[358]
GALNT11	OTANT9E6	moderate	Altered Expression	[336]
GLUD1	OTXKOCUH	moderate	Altered Expression	[359]
GLUD2	OTF3GGYY	moderate	Altered Expression	[359]
GNLY	OTZJKA8C	moderate	Biomarker	[360]
GOPC	OTRBGH71	moderate	Biomarker	[355]
GPM6A	OT8G13EG	moderate	Altered Expression	[361]
GPR151	OT7EACU6	moderate	Biomarker	[69]
HFM1	OTHV3EFE	moderate	Genetic Variation	[362]
HIP1R	OTIPKEJC	moderate	Altered Expression	[363]
HPX	OT14T7Q1	moderate	Biomarker	[364]
HVCN1	OT4ALYU4	moderate	Altered Expression	[365]
IRF2	OTAZRUW3	moderate	Altered Expression	[366]
ISG20	OTCWRJJW	moderate	Biomarker	[117]
KIR2DL5A	OT09FZE1	moderate	Genetic Variation	[77]
KIR2DL5B	OTSV0JL9	moderate	Genetic Variation	[77]
KIR2DS3	OT3PSLDL	moderate	Biomarker	[77]
LAMP3	OTN0XL3W	moderate	Biomarker	[367]
LCP1	OTK61F2A	moderate	Altered Expression	[368]
LCP2	OT57KE22	moderate	Biomarker	[369]
LDOC1	OTWZH4O9	moderate	Altered Expression	[370]
LMO1	OTB59SKB	moderate	Genetic Variation	[371]
LRIG1	OTY5HZN5	moderate	Altered Expression	[372]
LRP4	OTO4M459	moderate	Biomarker	[373]
LSAMP	OTYXVQX2	moderate	Biomarker	[367]
MARCHF8	OTH7PNN2	moderate	Altered Expression	[374]
MCPH1	OTYT3TT5	moderate	Biomarker	[58]
MLXIP	OT30UNI7	moderate	Altered Expression	[374]
MNDA	OTCTKR47	moderate	Altered Expression	[375]
MNX1	OTXP9FH1	moderate	Biomarker	[74]
MPRIP	OT5FV5NS	moderate	Altered Expression	[376]
MRGPRX3	OTRKCCDS	moderate	Biomarker	[69]
MRGPRX4	OTOBHZVA	moderate	Biomarker	[69]
MYBL2	OTZ3JX8Q	moderate	Altered Expression	[377]
MYCL	OT1MFQ5U	moderate	Biomarker	[378]
MYLIP	OTL0PFGV	moderate	Altered Expression	[374]
NCOA6	OTOMIGTV	moderate	Genetic Variation	[343]
NEUROD1	OTZQ7QJ2	moderate	Biomarker	[379]
NFATC1	OT4TMERS	moderate	Biomarker	[380]
NPAS2	OTMRT2TS	moderate	Genetic Variation	[381]
NUP98	OTNT12G2	moderate	Altered Expression	[382]
NXF2	OTJS5KTH	moderate	Biomarker	[383]
PARP9	OT7K4494	moderate	Altered Expression	[366]
PBX1	OTORABGO	moderate	Biomarker	[384]
PHLPP1	OTIFXW8D	moderate	Altered Expression	[385]
PIK3C2B	OTY2PROB	moderate	Biomarker	[361]
PPP1R12C	OT9Q86JO	moderate	Genetic Variation	[340]
PPP1R13B	OTC88VQO	moderate	Genetic Variation	[340]
PRELP	OT9EEBUJ	moderate	Biomarker	[386]
PRIMA1	OT9ITT3P	moderate	Biomarker	[387]
PSMG1	OTZ5I6UM	moderate	Biomarker	[57]
RELB	OTU3QYEF	moderate	Posttranslational Modification	[388]
RGCC	OTYJMLWM	moderate	Biomarker	[389]
RITA1	OTUH8IPS	moderate	Biomarker	[387]
RNF217	OTAX91ES	moderate	Altered Expression	[390]
RNF41	OTN1DQOY	moderate	Altered Expression	[372]
RPA1	OT76POLP	moderate	Altered Expression	[391]
RUNX1T1	OT30DED5	moderate	Biomarker	[259]
SALL1	OTYYZGLH	moderate	Biomarker	[392]
SDHB	OTRE1M1T	moderate	Genetic Variation	[393]
SH3BP4	OTVIRKW7	moderate	Genetic Variation	[394]
SLC2A4RG	OTW3LX8D	moderate	Altered Expression	[395]
SND1	OTT734JN	moderate	Genetic Variation	[343]
TARBP2	OT1QQ8H3	moderate	Genetic Variation	[343]
TCF7	OT1ID822	moderate	Altered Expression	[396]
TMEM132D	OTV6I4Z0	moderate	Biomarker	[397]
TNFSF18	OT3ANRX1	moderate	Altered Expression	[87]
TNFSF9	OTV9L89D	moderate	Biomarker	[398]
TNRC6B	OTGVT0SH	moderate	Genetic Variation	[343]
TRAT1	OTMPUNPD	moderate	Biomarker	[399]
TRIB2	OTHSX3MX	moderate	Altered Expression	[400]
TRIM63	OTUSWA74	moderate	Altered Expression	[401]
ACSBG1	OTM040MW	Strong	Biomarker	[402]
ADAM29	OTGLTTKU	Strong	Altered Expression	[403]
AGFG1	OTI8ZKC4	Strong	Biomarker	[404]
AIMP1	OTTA5C3U	Strong	Altered Expression	[405]
AK3	OTM59ZGG	Strong	Biomarker	[406]
ALDH7A1	OTV57BZD	Strong	Altered Expression	[195]
AMPD1	OTU17BCI	Strong	Genetic Variation	[407]
APAF1	OTJWIVY0	Strong	Altered Expression	[408]
ARHGAP20	OTG1STV8	Strong	Altered Expression	[409]
ARHGAP24	OTCQCEZS	Strong	Biomarker	[410]
ARHGEF2	OTBQTFRT	Strong	Biomarker	[411]
ARHGEF7	OT9BPJCL	Strong	Altered Expression	[412]
ASCC1	OTH4VAP9	Strong	Altered Expression	[412]
ASS1	OT4ZMG0Q	Strong	Altered Expression	[413]
ATAD1	OTJ02XFL	Strong	Biomarker	[414]
ATF2	OTNIZPEA	Strong	Biomarker	[415]
ATF5	OT03QCLM	Strong	Biomarker	[416]
ATN1	OTNZFLKY	Strong	Biomarker	[417]
BAG3	OTVXYUDQ	Strong	Altered Expression	[418]
BCL11B	OT8KKCVJ	Strong	Genetic Variation	[419]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[420]
BCL9	OTRBIPR4	Strong	Altered Expression	[297]
BID	OTOSHSHU	Strong	Biomarker	[33]
BIK	OTTH1T3D	Strong	Genetic Variation	[421]
BTG4	OTT3TKPI	Strong	Biomarker	[422]
C11orf21	OTJGXDHK	Strong	Genetic Variation	[125]
CARD11	OTRCTLYC	Strong	Genetic Variation	[423]
CBLL2	OTB4AD3V	Strong	Genetic Variation	[141]
CCL19	OTQ2UJMH	Strong	Biomarker	[275]
CCL28	OTY6XNQ7	Strong	Genetic Variation	[274]
CCL4	OT6B8P25	Strong	Biomarker	[105]
CCNH	OTKDU3SR	Strong	Genetic Variation	[424]
CD180	OTITK5E6	Strong	Biomarker	[425]
CD1C	OT4XINUJ	Strong	Altered Expression	[426]
CD1D	OT3ROU4J	Strong	Biomarker	[427]
CD247	OT45FGUX	Strong	Biomarker	[428]
CD53	OT9U5OXJ	Strong	Altered Expression	[429]
CD79A	OTOJC8DV	Strong	Altered Expression	[430]
CD84	OTAY5B0F	Strong	Altered Expression	[431]
CD8A	OTDWQJXK	Strong	Altered Expression	[432]
CD8B	OTMZ1T7J	Strong	Altered Expression	[432]
CDK2AP2	OTR99SJ8	Strong	Biomarker	[433]
CDKN3	OTBE3H07	Strong	Genetic Variation	[434]
CDR2	OTD3ZJST	Strong	Genetic Variation	[435]
CHD2	OTRKL6YC	Strong	Biomarker	[436]
CHST11	OTNJJ5Q1	Strong	Genetic Variation	[437]
CIB3	OT97EYB9	Strong	Genetic Variation	[186]
CLEC4D	OTT7X1UC	Strong	Genetic Variation	[438]
COLEC10	OTMBADGZ	Strong	Biomarker	[126]
COP1	OT6J2K12	Strong	Biomarker	[439]
CPEB1	OTLCXC6H	Strong	Biomarker	[325]
CREBRF	OT2GK1HI	Strong	Biomarker	[440]
CTTN	OTJRG4ES	Strong	Biomarker	[441]
CUL5	OTMTZD47	Strong	Biomarker	[442]
CXXC1	OTO10D1N	Strong	Altered Expression	[443]
CYLD	OT37FKH0	Strong	Biomarker	[444]
DAP	OT5YLL7E	Strong	Biomarker	[433]
DAPK1	OTNCNUCO	Strong	Posttranslational Modification	[445]
DCAF1	OT3ZDVOE	Strong	Biomarker	[404]
DCDC2	OTSUFH1H	Strong	Biomarker	[446]
DCTN6	OTI8PIN9	Strong	Altered Expression	[447]
DDX3X	OTDO4TRX	Strong	Genetic Variation	[283]
DERL3	OTRZRT6Q	Strong	Genetic Variation	[219]
DLEU7	OTVKX1YP	Strong	Biomarker	[448]
DLX3	OTARP5SQ	Strong	Genetic Variation	[449]
DNER	OT2GH2E5	Strong	Biomarker	[450]
DOK1	OTGVRLW6	Strong	Genetic Variation	[451]
DROSHA	OTCE68KZ	Strong	Genetic Variation	[343]
DTNB	OTX1HKM7	Strong	Genetic Variation	[186]
EGR3	OTGPJIRA	Strong	Altered Expression	[452]
ELL2	OTZJRTFM	Strong	Genetic Variation	[186]
ERCC2	OT1C8HQ4	Strong	Genetic Variation	[453]
ETV5	OTE2OBM4	Strong	Genetic Variation	[454]
ETV6	OTCZMG61	Strong	Biomarker	[455]
FADD	OTV7GFHH	Strong	Biomarker	[456]
FANCB	OTMZTXB5	Strong	Genetic Variation	[457]
FAU	OTGTVOWK	Strong	Biomarker	[458]
FCGR3B	OTSLSPZG	Strong	Biomarker	[459]
FCMR	OTI7I47T	Strong	Biomarker	[460]
FCRL1	OTXOYT29	Strong	Altered Expression	[461]
FCRL2	OT0RLDOD	Strong	Altered Expression	[462]
FCRL3	OTIFXFWL	Strong	Biomarker	[463]
FCRL4	OT3DVTRV	Strong	Biomarker	[464]
FCRL5	OTA7VHNE	Strong	Biomarker	[464]
FERMT3	OTFQOT3C	Strong	Biomarker	[465]
FH	OTEQWU6Q	Strong	Genetic Variation	[438]
FLG	OTE9QDV6	Strong	Biomarker	[466]
FMOD	OT9EJ5H8	Strong	Biomarker	[361]
FRZB	OTTO3DPY	Strong	Altered Expression	[467]
FZD3	OTIWDN78	Strong	Altered Expression	[468]
GAB1	OTQKE6V4	Strong	Altered Expression	[469]
GDE1	OTU6FSBF	Strong	Genetic Variation	[470]
GDF1	OTZ1VRBH	Strong	Altered Expression	[471]
GNB3	OTA6HYBA	Strong	Genetic Variation	[472]
GRB7	OTF8Y9XY	Strong	Altered Expression	[473]
HAS1	OTJIAG1W	Strong	Biomarker	[474]
HCLS1	OTX7WGYN	Strong	Altered Expression	[475]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[476]
HMMR	OT4M0JTZ	Strong	Biomarker	[477]
HOXA4	OTNVTQDT	Strong	Altered Expression	[478]
HOXB7	OTC7WYU8	Strong	Altered Expression	[479]
HPSE2	OTGEPP8V	Strong	Biomarker	[414]
IFI27	OTI2XGIT	Strong	Altered Expression	[447]
IFNGR1	OTCTQBWW	Strong	Biomarker	[426]
IGLL5	OT9XQFL5	Strong	Biomarker	[480]
IL2RG	OTRZ3OMY	Strong	Altered Expression	[481]
IL3	OT0CQ35N	Strong	Biomarker	[482]
IQGAP1	OTZRWTGA	Strong	Biomarker	[483]
ITGAX	OTOGIMHE	Strong	Genetic Variation	[471]
ITGB1BP1	OTVQFNGS	Strong	Biomarker	[465]
IVL	OT4VPNGY	Strong	Biomarker	[466]
JARID2	OT14UM8H	Strong	Altered Expression	[484]
KHSRP	OTDHZARB	Strong	Altered Expression	[485]
KLHL7	OT2OF1O8	Strong	Biomarker	[486]
KLRC4	OTXOSGIB	Strong	Biomarker	[114]
KRT31	OTB6RCAH	Strong	Genetic Variation	[487]
LAMTOR2	OTHEDISB	Strong	Biomarker	[433]
LBR	OT1HG3HG	Strong	Biomarker	[488]
LEF1	OTWS5I5H	Strong	Altered Expression	[441]
LIG4	OT40DNXU	Strong	Altered Expression	[489]
LPP	OT6TU8SE	Strong	Genetic Variation	[186]
MAGED4B	OTO37U7W	Strong	Biomarker	[177]
MARCKSL1	OT13J2FM	Strong	Genetic Variation	[92]
MED12	OTQZ4D2X	Strong	Genetic Variation	[25]
MGA	OTTLB216	Strong	Genetic Variation	[490]
MIB1	OT5C404P	Strong	Altered Expression	[491]
MRO	OT5U38CP	Strong	Genetic Variation	[492]
MRPL28	OT4LUTZU	Strong	Biomarker	[213]
MUL1	OT2JC9YR	Strong	Genetic Variation	[141]
MXD1	OTS5CTHX	Strong	Genetic Variation	[407]
MXI1	OTUQ9E0D	Strong	Biomarker	[33]
MYEOV	OTDC7UHL	Strong	Biomarker	[493]
MZB1	OT071TET	Strong	Altered Expression	[494]
NCAPH2	OTSASNX6	Strong	Genetic Variation	[186]
NCKAP1L	OTADCEUK	Strong	Biomarker	[495]
NPAT	OT1ZU6JB	Strong	Biomarker	[442]
NRIP1	OTIZOJQV	Strong	Altered Expression	[496]
NXT1	OT0VO6AY	Strong	Biomarker	[213]
OCA2	OTDWIGBF	Strong	Biomarker	[497]
PACC1	OTKBS8CC	Strong	Biomarker	[498]
PAGR1	OTXR5PQ8	Strong	Biomarker	[147]
PDIK1L	OTISF4KG	Strong	Biomarker	[130]
PEA15	OTKCKTSX	Strong	Biomarker	[497]
PEG10	OTWD2278	Strong	Altered Expression	[499]
PENK	OT8P3HMP	Strong	Altered Expression	[500]
PER2	OTU2B1DJ	Strong	Altered Expression	[501]
PIEZO1	OTBG1FU4	Strong	Biomarker	[466]
PIK3R2	OTZSUQK5	Strong	Posttranslational Modification	[502]
PLAG1	OTT9AJQY	Strong	Altered Expression	[503]
PLXNB1	OTCA7JIT	Strong	Biomarker	[504]
POT1	OTNBXJCQ	Strong	Genetic Variation	[505]
POU2AF1	OTOO6WHL	Strong	Altered Expression	[506]
POU2F2	OTPV0J0C	Strong	Altered Expression	[214]
PPP1R13L	OTNCPLWE	Strong	Altered Expression	[471]
PPP2R5C	OTF7CGO2	Strong	Biomarker	[507]
PRDM1	OTQLSVBS	Strong	Altered Expression	[508]
PSMD9	OT6Y5CC3	Strong	Altered Expression	[447]
PTPA	OTRGFOI7	Strong	Posttranslational Modification	[509]
PTPN4	OT6SXU5Y	Strong	Biomarker	[510]
PTPRO	OTFLKWOY	Strong	Biomarker	[511]
RAG1	OTV131E4	Strong	Altered Expression	[214]
RAPH1	OTMQXW7S	Strong	Biomarker	[402]
RARS1	OTHPZ6JN	Strong	Altered Expression	[405]
RB1	OT9VMY7B	Strong	Genetic Variation	[512]
RBL2	OTBQSOE6	Strong	Biomarker	[507]
RCBTB1	OTAYELI8	Strong	Altered Expression	[281]
RHOH	OT1J9SEB	Strong	Genetic Variation	[513]
RNH1	OT6EC79B	Strong	Altered Expression	[471]
RPAIN	OTBMXAYK	Strong	Biomarker	[404]
RPL10	OTBHOZGC	Strong	Genetic Variation	[514]
RPP14	OT4OYFSK	Strong	Biomarker	[433]
RPS15	OT0WYZYG	Strong	Genetic Variation	[514]
RTL10	OTHGB81W	Strong	Biomarker	[515]
SAMHD1	OTBCIBC7	Strong	Genetic Variation	[516]
SEMG1	OT6Z4BPQ	Strong	Altered Expression	[517]
SERPINA5	OTTZXPGD	Strong	Biomarker	[518]
SET	OTGYYQJO	Strong	Altered Expression	[509]
SETDB2	OTBVVP9Q	Strong	Biomarker	[519]
SF3B2	OTNW2U4Y	Strong	Genetic Variation	[190]
SF3B6	OTPRKS6S	Strong	Biomarker	[433]
SFRP1	OT0U9G41	Strong	Biomarker	[213]
SFRP2	OT8GZ0CA	Strong	Biomarker	[213]
SFRP5	OTLCVVSH	Strong	Biomarker	[213]
SHC3	OT305NPA	Strong	Altered Expression	[471]
SIGLEC7	OTNDLURR	Strong	Altered Expression	[485]
SLAMF1	OTBTT3ZQ	Strong	Biomarker	[425]
SLC7A4	OTAVC6QS	Strong	Biomarker	[520]
SNRPN	OTQB1ID1	Strong	Genetic Variation	[521]
SOX11	OT4LG7LA	Strong	Biomarker	[522]
SPANXA1	OTMK3QIS	Strong	Altered Expression	[523]
SPRYD7	OT6FTW9Z	Strong	Biomarker	[524]
ST13	OTNML6UP	Strong	Biomarker	[524]
STAT5A	OTBSJGN3	Strong	Altered Expression	[157]
STAT5B	OTZVPEBT	Strong	Altered Expression	[157]
STIL	OT9799VN	Strong	Biomarker	[201]
STUB1	OTSUYI9A	Strong	Biomarker	[525]
SUB1	OTK71JYU	Strong	Biomarker	[213]
TCIM	OTARUXQF	Strong	Genetic Variation	[526]
TERF2IP	OT3M5P3G	Strong	Biomarker	[308]
TFG	OT2KJENI	Strong	Biomarker	[527]
TFR2	OTMYCCEO	Strong	Altered Expression	[220]
TIA1	OTGPN3P8	Strong	Genetic Variation	[528]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[447]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[529]
TMED7	OTONO8E6	Strong	Altered Expression	[447]
TMOD4	OTXLGJ4R	Strong	Altered Expression	[530]
TNFRSF10C	OTVHOL9B	Strong	Altered Expression	[531]
TNFSF8	OTDYGDJ3	Strong	Altered Expression	[532]
TOPBP1	OT6UPZPD	Strong	Biomarker	[114]
TP73	OT0LUO47	Strong	Biomarker	[533]
TRAF1	OTTLM5RU	Strong	Altered Expression	[534]
TRAF2	OT1MEZZN	Strong	Genetic Variation	[535]
TRIM33	OT0KS4J7	Strong	Altered Expression	[140]
ARR3	OTRZ00CH	Definitive	Biomarker	[239]
BANK1	OTXAAA11	Definitive	Genetic Variation	[125]
BCL2L11	OTNQQWFJ	Definitive	Biomarker	[33]
BCL3	OT1M5B95	Definitive	Biomarker	[536]
BCR	OTCN76C1	Definitive	Biomarker	[287]
CXADR	OT9ZP02A	Definitive	Biomarker	[239]
GPR37	OTIMDDI3	Definitive	Genetic Variation	[125]
GRAMD1B	OTCG1GX2	Definitive	Genetic Variation	[125]
HDLBP	OTKDEEYX	Definitive	Genetic Variation	[207]
IBTK	OTB2GM4G	Definitive	Biomarker	[537]
ILRUN	OTE8FHQD	Definitive	Genetic Variation	[125]
KRT20	OT4RB40L	Definitive	Biomarker	[243]
LRRC34	OTSPZLKF	Definitive	Genetic Variation	[102]
MGAT5	OTU4DD4G	Definitive	Genetic Variation	[102]
OAS3	OT6E5FYS	Definitive	Genetic Variation	[125]
RHOU	OTERIAD4	Definitive	Genetic Variation	[125]
RREB1	OT62460U	Definitive	Genetic Variation	[102]
RTEL1	OTI3PJCT	Definitive	Biomarker	[538]
SERPINB6	OT7G55IK	Definitive	Genetic Variation	[207]
SP110	OTFW6WH7	Definitive	Genetic Variation	[207]
SPG7	OT8OY9ST	Definitive	Biomarker	[239]
TRIM13	OTQIUACB	Definitive	Biomarker	[239]

References

• [1] Chlorambucil FDA Label
• [2] Ibrutinib FDA Label
• [3] Idelalisib FDA Label
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Mechlorethamine FDA Label
• [6] Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e879-e890.
• [7] Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353-1363.
• [8] ClinicalTrials.gov (NCT04666038) Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL. U.S. National Institutes of Health.
• [9] Prednisone FDA Label
• [10] Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
• [11] Uracil mustard FDA Label
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] ClinicalTrials.gov (NCT04578613) ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT00942409) Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT04494503) Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT04155710) Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT04030195) Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03960840) CD19-specific CAR-T Cells in CLL/SLL and DLBCL. U.S. National Institutes of Health.
• [20] Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.J Immunol Res. 2017;2017:7304658. doi: 10.1155/2017/7304658. Epub 2017 Dec 17.
• [21] Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.Clin Cancer Res. 2016 Dec 15;22(24):6217-6227. doi: 10.1158/1078-0432.CCR-15-2903. Epub 2016 Mar 8.
• [22] HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.Cancers (Basel). 2019 Apr 23;11(4):575. doi: 10.3390/cancers11040575.
• [23] In-ovo exposed carbon black nanoparticles altered mRNA gene transcripts of antioxidants, proinflammatory and apoptotic pathways in the brain of chicken embryos.Chem Biol Interact. 2018 Nov 1;295:133-139. doi: 10.1016/j.cbi.2018.02.031. Epub 2018 Feb 26.
• [24] Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.Int J Mol Sci. 2017 Oct 27;18(11):2259. doi: 10.3390/ijms18112259.
• [25] MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.Br J Haematol. 2017 Nov;179(3):421-429. doi: 10.1111/bjh.14869. Epub 2017 Aug 2.
• [26] CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.Int J Mol Sci. 2019 Jun 5;20(11):2764. doi: 10.3390/ijms20112764.
• [27] Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.Cancer Res. 2019 May 15;79(10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. Epub 2019 Apr 2.
• [28] Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.Blood. 2018 Jun 28;131(26):2943-2954. doi: 10.1182/blood-2017-10-813931. Epub 2018 Apr 25.
• [29] EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.Blood. 2017 Feb 16;129(7):866-878. doi: 10.1182/blood-2016-02-697185. Epub 2016 Dec 21.
• [30] The future of chronic lymphocytic leukemia: potential directions from ASH 2017.Expert Rev Hematol. 2018 Jun;11(6):481-486. doi: 10.1080/17474086.2018.1480364. Epub 2018 Jun 6.
• [31] Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies.Methods Mol Biol. 2016;1436:129-45. doi: 10.1007/978-1-4939-3667-0_10.
• [32] Aberrant histone modification in CD19(+) B cells of patients with chronic lymphocytic leukemia.Onco Targets Ther. 2017 Feb 23;10:1173-1179. doi: 10.2147/OTT.S121301. eCollection 2017.
• [33] Mitotic slippage: an old tale with a new twist.Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.
• [34] Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.J Immunol. 2018 Sep 1;201(5):1570-1585. doi: 10.4049/jimmunol.1800591. Epub 2018 Aug 1.
• [35] Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro.Biomed Pharmacother. 2018 Jul;103:915-922. doi: 10.1016/j.biopha.2018.04.122. Epub 2018 Apr 24.
• [36] Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.Med Oncol. 2018 Nov 13;36(1):3. doi: 10.1007/s12032-018-1226-0.
• [37] mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.Clin Chem Lab Med. 2016 Feb;54(2):315-24. doi: 10.1515/cclm-2015-0456.
• [38] Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.Environ Mol Mutagen. 2017 Dec;58(9):654-661. doi: 10.1002/em.22128. Epub 2017 Aug 19.
• [39] MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.Cell Death Differ. 2016 Feb;23(2):242-52. doi: 10.1038/cdd.2015.87. Epub 2015 Jul 3.
• [40] Underlying mechanisms behind the protective effect of angiotensin (1-7) in experimental rat model of ovarian ischemia reperfusion injury.Life Sci. 2019 Oct 15;235:116840. doi: 10.1016/j.lfs.2019.116840. Epub 2019 Sep 5.
• [41] Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.Leuk Lymphoma. 2019 May;60(5):1266-1274. doi: 10.1080/10428194.2018.1523400. Epub 2019 Feb 4.
• [42] Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.Oncogene. 2018 Oct;37(41):5520-5533. doi: 10.1038/s41388-018-0333-x. Epub 2018 Jun 12.
• [43] Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.Leuk Lymphoma. 2016 May;57(5):1054-9. doi: 10.3109/10428194.2015.1092527. Epub 2015 Oct 19.
• [44] Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis.Oncogene. 2018 Feb 8;37(6):756-767. doi: 10.1038/onc.2017.365. Epub 2017 Oct 23.
• [45] Molecular genetics and targeted therapy of WNT-related human diseases (Review).Int J Mol Med. 2017 Sep;40(3):587-606. doi: 10.3892/ijmm.2017.3071. Epub 2017 Jul 19.
• [46] SLAMF6 as a Regulator of Exhausted CD8(+) T Cells in Cancer.Cancer Immunol Res. 2019 Sep;7(9):1485-1496. doi: 10.1158/2326-6066.CIR-18-0664. Epub 2019 Jul 17.
• [47] Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.Tumour Biol. 2016 Jul;37(7):9473-81. doi: 10.1007/s13277-016-4846-z. Epub 2016 Jan 20.
• [48] Expression of CD43 in chronic lymphoproliferative leukemias.Cytometry B Clin Cytom. 2018 Jan;94(1):136-142. doi: 10.1002/cyto.b.21509. Epub 2017 Jan 25.
• [49] TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.Oncoimmunology. 2017 Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017.
• [50] Structural and functional analysis of the human POT1-TPP1 telomeric complex.Nat Commun. 2017 Apr 10;8:14928. doi: 10.1038/ncomms14928.
• [51] High-Throughput Sequencing of the T-Cell Receptor Beta Chain Gene Repertoire in Chronic Lymphocytic Leukemia.Methods Mol Biol. 2019;1881:355-363. doi: 10.1007/978-1-4939-8876-1_24.
• [52] Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking.J Vis Exp. 2019 Oct 23;(152). doi: 10.3791/60426.
• [53] Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.Hum Mol Genet. 2017 Jan 15;26(2):344-353. doi: 10.1093/hmg/ddw427.
• [54] Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.Blood. 2011 Feb 10;117(6):1911-6. doi: 10.1182/blood-2010-09-308205. Epub 2010 Dec 3.
• [55] Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.Tissue Antigens. 2015 Oct;86(4):279-84. doi: 10.1111/tan.12641. Epub 2015 Aug 13.
• [56] c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.Blood. 2008 Dec 15;112(13):5141-9. doi: 10.1182/blood-2008-03-146704. Epub 2008 Sep 16.
• [57] Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.Blood. 2015 Feb 12;125(7):1126-36. doi: 10.1182/blood-2014-01-546796. Epub 2014 Dec 23.
• [58] MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia.FEBS J. 2015 May;282(10):1939-52. doi: 10.1111/febs.13245. Epub 2015 Mar 9.
• [59] The expression pattern of Bcl11a, Mdm2 and Pten genes in B-cell acute lymphoblastic leukemia.Asia Pac J Clin Oncol. 2018 Apr;14(2):e124-e128. doi: 10.1111/ajco.12690. Epub 2017 May 24.
• [60] miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w.Oncol Rep. 2013 Aug;30(2):701-6. doi: 10.3892/or.2013.2482. Epub 2013 May 23.
• [61] Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins.J Leukoc Biol. 2016 Nov;100(5):1061-1070. doi: 10.1189/jlb.2AB0715-301R. Epub 2016 Jun 16.
• [62] Single-nucleotide polymorphisms in genes encoding for CC chemokines were not associated with the risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1332-5. doi: 10.1158/1055-9965.EPI-13-0328. Epub 2013 May 2.
• [63] Expression feature of CD3, FcRI, and Zap-70 in patients with chronic lymphocytic leukemia.Hematology. 2012 Mar;17(2):71-5. doi: 10.1179/102453312X13221316477895.
• [64] Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.Mol Cancer Ther. 2011 Sep;10(9):1624-34. doi: 10.1158/1535-7163.MCT-10-1119. Epub 2011 Jul 18.
• [65] Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.Blood. 2012 Oct 4;120(14):2853-63. doi: 10.1182/blood-2012-02-413252. Epub 2012 Aug 20.
• [66] STAT3-activated GM-CSFR translocates to the nucleus and protects CLL cells from apoptosis.Mol Cancer Res. 2014 Sep;12(9):1267-82. doi: 10.1158/1541-7786.MCR-13-0652-T. Epub 2014 May 16.
• [67] Advances in basic and clinical immunology in 2014.J Allergy Clin Immunol. 2015 May;135(5):1132-41. doi: 10.1016/j.jaci.2015.02.037.
• [68] Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia.Tumour Biol. 2013 Dec;34(6):3579-85. doi: 10.1007/s13277-013-0937-2. Epub 2013 Jun 27.
• [69] The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia.Leuk Lymphoma. 2012 Apr;53(4):665-73. doi: 10.3109/10428194.2011.625578.
• [70] Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.Exp Hematol. 2010 Dec;38(12):1167-77. doi: 10.1016/j.exphem.2010.08.008. Epub 2010 Sep 24.
• [71] Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia.Cancer Biol Ther. 2010 Jul 15;10(2):180-9. doi: 10.4161/cbt.10.2.12168. Epub 2010 Jul 26.
• [72] Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells.Leuk Res. 2009 Mar;33(3):395-406. doi: 10.1016/j.leukres.2008.08.010. Epub 2008 Sep 26.
• [73] The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL).Leuk Res. 2008 Dec;32(12):1815-9. doi: 10.1016/j.leukres.2008.04.008. Epub 2008 May 21.
• [74] Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.Am J Hematol. 2012 Apr;87(4):361-7. doi: 10.1002/ajh.23115. Epub 2012 Feb 28.
• [75] Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Blood. 2011 Jan 13;117(2):585-90. doi: 10.1182/blood-2010-07-295097. Epub 2010 Oct 15.
• [76] A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.Biochim Biophys Acta. 2014 Oct;1843(10):2240-52. doi: 10.1016/j.bbamcr.2014.04.017. Epub 2014 Apr 21.
• [77] KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease.Tissue Antigens. 2011 Aug;78(2):129-38. doi: 10.1111/j.1399-0039.2011.01721.x.
• [78] KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia.Clin Biochem. 2015 Sep;48(13-14):849-54. doi: 10.1016/j.clinbiochem.2015.04.007. Epub 2015 Apr 17.
• [79] Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.Cancer Immunol Immunother. 2013 Nov;62(11):1697-1709. doi: 10.1007/s00262-013-1473-z.
• [80] Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.Blood. 2009 Nov 5;114(19):4150-7. doi: 10.1182/blood-2009-03-212852. Epub 2009 Sep 4.
• [81] Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K in Mature B-cell Malignancies.Clin Cancer Res. 2018 Mar 1;24(5):1103-1113. doi: 10.1158/1078-0432.CCR-17-2218. Epub 2017 Dec 15.
• [82] Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.Br J Haematol. 2009 Dec;147(5):641-52. doi: 10.1111/j.1365-2141.2009.07900.x. Epub 2009 Sep 18.
• [83] Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.Blood. 2010 Aug 19;116(7):1083-91. doi: 10.1182/blood-2009-10-246199. Epub 2010 May 4.
• [84] S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis.Blood. 2012 Nov 22;120(22):4391-9. doi: 10.1182/blood-2012-04-425959. Epub 2012 Oct 1.
• [85] Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F330-8. doi: 10.1152/ajprenal.00467.2014. Epub 2014 Dec 4.
• [86] Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Leuk Lymphoma. 2014 Sep;55(9):2085-92. doi: 10.3109/10428194.2013.867486. Epub 2014 Jan 24.
• [87] Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.Mol Ther. 2013 Apr;21(4):877-86. doi: 10.1038/mt.2013.11. Epub 2013 Feb 5.
• [88] Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.Oncotarget. 2015 Oct 13;6(31):32061-74. doi: 10.18632/oncotarget.5201.
• [89] CIP4 controls CCL19-driven cell steering and chemotaxis in chronic lymphocytic leukemia.Cancer Res. 2013 Jun 1;73(11):3412-24. doi: 10.1158/0008-5472.CAN-12-3564. Epub 2013 May 3.
• [90] Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and Treatment.PLoS One. 2016 Apr 14;11(4):e0148500. doi: 10.1371/journal.pone.0148500. eCollection 2016.
• [91] MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia.Leuk Lymphoma. 2006 Nov;47(11):2308-13. doi: 10.1080/10428190600881421.
• [92] Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia.Leuk Lymphoma. 2002 Jan;43(1):153-8. doi: 10.1080/10428190210198.
• [93] A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia--a possible new therapeutic target.Hematology. 2012 May;17(3):132-9. doi: 10.1179/102453312X13376952196296.
• [94] Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.Hum Pathol. 2011 Dec;42(12):1989-2000. doi: 10.1016/j.humpath.2011.02.027. Epub 2011 Jul 5.
• [95] Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews.Eur J Haematol. 2017 Jul;99(1):51-55. doi: 10.1111/ejh.12889. Epub 2017 May 3.
• [96] Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.
• [97] Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells.BMC Complement Altern Med. 2017 Oct 4;17(1):477. doi: 10.1186/s12906-017-1956-0.
• [98] Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.Haematologica. 2020 Jan 31;105(2):448-456. doi: 10.3324/haematol.2019.219550. Print 2020.
• [99] Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.
• [100] Tumor suppressors BTG1 and BTG2: Beyond growth control.J Cell Physiol. 2019 May;234(5):5379-5389. doi: 10.1002/jcp.27407. Epub 2018 Oct 23.
• [101] Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):137-145. doi: 10.1007/s00005-016-0430-x. Epub 2016 Dec 8.
• [102] Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.Genet Epidemiol. 2019 Oct;43(7):844-863. doi: 10.1002/gepi.22242. Epub 2019 Aug 13.
• [103] Gatifloxacin inducing apoptosis of stromal fibroblasts through cross-talk between caspase-dependent extrinsic and intrinsic pathways.Int J Ophthalmol. 2019 Oct 18;12(10):1524-1530. doi: 10.18240/ijo.2019.10.02. eCollection 2019.
• [104] CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.Oncotarget. 2015 May 20;6(14):12048-60. doi: 10.18632/oncotarget.3660.
• [105] Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3.
• [106] Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.Oncotarget. 2016 Jun 28;7(26):40558-40570. doi: 10.18632/oncotarget.9941.
• [107] Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.
• [108] Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.Blood Cancer J. 2015 Jan 23;5(1):e273. doi: 10.1038/bcj.2014.92.
• [109] Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2008 Jul;74(4):221-6. doi: 10.1002/cyto.b.20423.
• [110] CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. Online ahead of print.
• [111] Cellular origin and pathophysiology of chronic lymphocytic leukemia.J Exp Med. 2012 Nov 19;209(12):2183-98. doi: 10.1084/jem.20120833. Epub 2012 Oct 22.
• [112] InVivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2.
• [113] Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7.
• [114] Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.Blood. 2008 Feb 1;111(3):1625-33. doi: 10.1182/blood-2007-08-110130. Epub 2007 Nov 15.
• [115] Nurse-like cells promote CLL survival through LFA-3/CD2 interactions.Oncotarget. 2016 Nov 26;8(32):52225-52236. doi: 10.18632/oncotarget.13660. eCollection 2017 Aug 8.
• [116] Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy.Int J Hematol. 2016 Sep;104(3):368-77. doi: 10.1007/s12185-016-2034-y. Epub 2016 Jul 8.
• [117] Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.Adv Clin Exp Med. 2018 Jul;27(7):987-999. doi: 10.17219/acem/74437.
• [118] Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.Br J Haematol. 1999 Sep;106(4):995-1004. doi: 10.1046/j.1365-2141.1999.01642.x.
• [119] TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner.J Immunol. 2010 May 1;184(9):4761-9. doi: 10.4049/jimmunol.0904149. Epub 2010 Mar 31.
• [120] Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.J Immunol. 2019 May 1;202(9):2806-2816. doi: 10.4049/jimmunol.1801359. Epub 2019 Mar 25.
• [121] The soluble form of CD83 is present at elevated levels in a number of hematological malignancies.Leuk Res. 2004 Mar;28(3):237-41. doi: 10.1016/s0145-2126(03)00255-8.
• [122] The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells.Pathol Oncol Res. 2019 Apr;25(2):647-652. doi: 10.1007/s12253-018-0512-7. Epub 2018 Nov 8.
• [123] Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.Int J Oncol. 2004 Sep;25(3):579-95.
• [124] Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.Oncotarget. 2018 May 29;9(41):26353-26369. doi: 10.18632/oncotarget.25293. eCollection 2018 May 29.
• [125] Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.Nat Commun. 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175.
• [126] Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.Ann Hematol. 2019 Feb;98(2):437-443. doi: 10.1007/s00277-018-3525-0. Epub 2018 Oct 18.
• [127] Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.Eur J Haematol. 2000 Jan;64(1):3-9. doi: 10.1034/j.1600-0609.2000.80097.x.
• [128] A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.Oncotarget. 2015 Oct 20;6(32):32669-80. doi: 10.18632/oncotarget.5404.
• [129] Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia.PLoS One. 2012;7(3):e34347. doi: 10.1371/journal.pone.0034347. Epub 2012 Mar 28.
• [130] Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
• [131] p53 abnormalities in B-cell prolymphocytic leukemia.Blood. 1997 Mar 15;89(6):2015-23.
• [132] Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.Blood. 2007 Nov 1;110(9):3316-25. doi: 10.1182/blood-2007-05-089409. Epub 2007 Jul 25.
• [133] Molecular Players in Hematologic Tumor Cell Trafficking.Front Immunol. 2019 Feb 6;10:156. doi: 10.3389/fimmu.2019.00156. eCollection 2019.
• [134] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.Leuk Lymphoma. 2017 Jun;58(6):1376-1383. doi: 10.1080/10428194.2016.1251592. Epub 2016 Nov 8.
• [135] Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.Cancer Genet Cytogenet. 1999 Apr 15;110(2):77-81. doi: 10.1016/s0165-4608(98)00207-6.
• [136] Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.Int J Mol Med. 2004 Jul;14(1):113-9.
• [137] Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.Cancer Biol Ther. 2012 Dec;13(14):1522-8. doi: 10.4161/cbt.22252. Epub 2012 Oct 10.
• [138] Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.PLoS One. 2014 Feb 24;9(2):e89577. doi: 10.1371/journal.pone.0089577. eCollection 2014.
• [139] Loss of PKR activity in chronic lymphocytic leukemia.Int J Cancer. 2004 Apr 10;109(3):329-35. doi: 10.1002/ijc.11714.
• [140] Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.Crit Rev Oncol Hematol. 2018 Jun;126:24-31. doi: 10.1016/j.critrevonc.2018.03.022. Epub 2018 Mar 29.
• [141] FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.Blood. 2019 Feb 21;133(8):830-839. doi: 10.1182/blood-2018-09-874529. Epub 2018 Dec 3.
• [142] Obinutuzumab activates FcRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL).Oncoimmunology. 2018 Feb 12;7(6):e1428158. doi: 10.1080/2162402X.2018.1428158. eCollection 2018.
• [143] FcRIIb expression in early stage chronic lymphocytic leukemia.Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4.
• [144] Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt.Biochem Biophys Res Commun. 2003 Nov 14;311(2):365-71. doi: 10.1016/j.bbrc.2003.10.012.
• [145] MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.Leukemia. 2019 Feb;33(2):403-414. doi: 10.1038/s41375-018-0230-x. Epub 2018 Aug 15.
• [146] Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia.Oncol Lett. 2019 Jan;17(1):1019-1029. doi: 10.3892/ol.2018.9656. Epub 2018 Nov 1.
• [147] Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells.Oncogene. 2000 Jan 13;19(2):265-72. doi: 10.1038/sj.onc.1203292.
• [148] Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis.Int J Oncol. 2016 Oct;49(4):1469-78. doi: 10.3892/ijo.2016.3623. Epub 2016 Jul 15.
• [149] Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.Life Sci. 2019 Sep 1;232:116583. doi: 10.1016/j.lfs.2019.116583. Epub 2019 Jun 18.
• [150] Histidine decarboxylase in peripheral lymphocytes of healthy individuals and chronic lymphoid leukemia patients.Pathol Oncol Res. 1998;4(2):121-4. doi: 10.1007/BF02904705.
• [151] HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.Int J Cancer. 2019 Dec 1;145(11):3089-3100. doi: 10.1002/ijc.32383. Epub 2019 May 15.
• [152] ICOS gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population.Folia Histochem Cytobiol. 2011;49(1):49-54. doi: 10.5603/fhc.2011.0008.
• [153] Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.Expert Rev Hematol. 2020 Jan;13(1):31-38. doi: 10.1080/17474086.2020.1697226. Epub 2019 Dec 10.
• [154] Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups.Leukemia. 2018 Feb;32(2):332-342. doi: 10.1038/leu.2017.177. Epub 2017 Jun 6.
• [155] Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia.Leuk Lymphoma. 2001 Jun;42(1-2):195-205. doi: 10.3109/10428190109097691.
• [156] Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.Blood. 2008 Aug 1;112(3):750-9. doi: 10.1182/blood-2008-02-139378. Epub 2008 May 12.
• [157] Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.J Immunol. 2019 May 15;202(10):2924-2944. doi: 10.4049/jimmunol.1801142. Epub 2019 Apr 15.
• [158] Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes.Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):144-54. doi: 10.1158/1078-0432.ccr-1026-3.
• [159] Complex karyotypic evolution in B-cell chronic lymphocytic leukemia.Cancer Genet Cytogenet. 1991 Dec;57(2):187-94. doi: 10.1016/0165-4608(91)90151-j.
• [160] CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-B mediated pathway.Oncotarget. 2015 Jun 30;6(18):15931-9. doi: 10.18632/oncotarget.3285.
• [161] IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.J Immunol. 2008 Nov 1;181(9):6051-60. doi: 10.4049/jimmunol.181.9.6051.
• [162] B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.Br J Haematol. 2014 Feb;164(4):570-8. doi: 10.1111/bjh.12645. Epub 2013 Nov 18.
• [163] Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.J Cell Physiol. 2019 Aug;234(8):13994-14006. doi: 10.1002/jcp.28086. Epub 2019 Jan 8.
• [164] Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells.Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1416-20. doi: 10.1073/pnas.92.5.1416.
• [165] Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia.Oncol Rep. 2018 Jun;39(6):3064-3072. doi: 10.3892/or.2018.6367. Epub 2018 Apr 12.
• [166] Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.Leukemia. 2020 Jan;34(1):100-114. doi: 10.1038/s41375-019-0507-8. Epub 2019 Jun 13.
• [167] A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.Nat Genet. 2014 Jan;46(1):56-60. doi: 10.1038/ng.2843. Epub 2013 Dec 1.
• [168] Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.Oncotarget. 2016 Jan 12;7(2):1477-85. doi: 10.18632/oncotarget.6395.
• [169] Role of LFA-1 and ICAM-1 in Cancer.Cancers (Basel). 2017 Nov 3;9(11):153. doi: 10.3390/cancers9110153.
• [170] Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications.Methods Mol Biol. 2019;1881:101-112. doi: 10.1007/978-1-4939-8876-1_8.
• [171] IL-4 enhances expression and function of surface IgM in CLL cells.Blood. 2016 Jun 16;127(24):3015-25. doi: 10.1182/blood-2015-11-682906. Epub 2016 Mar 21.
• [172] Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2.
• [173] Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.Cancer. 2008 Oct 25;114(5):315-22. doi: 10.1002/cncr.23796.
• [174] Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2007 Sep;72(5):354-62. doi: 10.1002/cyto.b.20164.
• [175] Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.Blood. 2017 Nov 2;130(18):2006-2017. doi: 10.1182/blood-2017-03-775858. Epub 2017 Sep 20.
• [176] Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.Haematologica. 2003 Jun;88(6):654-8.
• [177] Expression of the MAGE gene family in human lymphocytic leukemia.Cancer Immunol Immunother. 1995 Aug;41(2):90-103. doi: 10.1007/s002620050205.
• [178] Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.Leuk Lymphoma. 2019 Jul;60(7):1632-1643. doi: 10.1080/10428194.2018.1542148. Epub 2019 Jan 16.
• [179] Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.Leukemia. 2017 Jan;31(1):170-176. doi: 10.1038/leu.2016.172. Epub 2016 Jun 14.
• [180] Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.Cancer Res. 2015 Oct 1;75(19):4153-63. doi: 10.1158/0008-5472.CAN-15-0986. Epub 2015 Aug 17.
• [181] ILK Induction in Lymphoid Organs by a TNF-NF-B-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.Cancer Res. 2016 Apr 15;76(8):2186-96. doi: 10.1158/0008-5472.CAN-15-3379. Epub 2016 Feb 2.
• [182] Bruton's tyrosine kinase inhibitor restrains Wntsignaling in chronic lymphocytic leukemia.Mol Med Rep. 2016 Jun;13(6):4934-8. doi: 10.3892/mmr.2016.5111. Epub 2016 Apr 12.
• [183] The influence of MTHFR C677T polymorphism in chronic lymphocytic leukemia.Electrophoresis. 2019 Jul;40(12-13):1715-1718. doi: 10.1002/elps.201800402. Epub 2019 May 2.
• [184] The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.Leuk Lymphoma. 2020 Mar;61(3):510-524. doi: 10.1080/10428194.2019.1675877. Epub 2019 Oct 20.
• [185] Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.Blood. 2010 May 13;115(19):3907-15. doi: 10.1182/blood-2009-09-244251. Epub 2010 Jan 28.
• [186] Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.
• [187] Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.Nat Commun. 2018 Sep 21;9(1):3839. doi: 10.1038/s41467-018-06069-5.
• [188] NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.
• [189] In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment.Cancers (Basel). 2019 Dec 4;11(12):1939. doi: 10.3390/cancers11121939.
• [190] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [191] Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.Cancers (Basel). 2019 Mar 1;11(3):291. doi: 10.3390/cancers11030291.
• [192] Par-4 overexpression impedes leukemogenesis in the E-TCL1 leukemia model through downregulation of NF-B signaling.Blood Adv. 2019 Apr 23;3(8):1255-1266. doi: 10.1182/bloodadvances.2018025973.
• [193] Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.Virchows Arch. 2019 Dec;475(6):795-798. doi: 10.1007/s00428-019-02608-7. Epub 2019 Jul 17.
• [194] Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study.Cancer Manag Res. 2019 Aug 12;11:7605-7618. doi: 10.2147/CMAR.S212069. eCollection 2019.
• [195] Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.Blood. 1998 Oct 1;92(7):2484-94.
• [196] Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.Int J Cancer. 2011 Sep 1;129(5):1162-9. doi: 10.1002/ijc.25785. Epub 2011 Feb 11.
• [197] Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.Clin Cancer Res. 2002 Feb;8(2):589-95.
• [198] Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.Cell Signal. 2017 Dec;40:73-80. doi: 10.1016/j.cellsig.2017.08.011. Epub 2017 Sep 1.
• [199] Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study.Acta Haematol. 2018;139(2):132-139. doi: 10.1159/000486361. Epub 2018 Feb 14.
• [200] Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia.Adv Clin Exp Med. 2019 Mar;28(3):385-390. doi: 10.17219/acem/90771.
• [201] Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies.Br J Haematol. 1995 Dec;91(4):871-7. doi: 10.1111/j.1365-2141.1995.tb05403.x.
• [202] Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.Leuk Res. 2009 Sep;33(9):1276-81. doi: 10.1016/j.leukres.2008.10.010. Epub 2008 Nov 21.
• [203] Multipronged functional proteomics approaches for global identification of altered cell signalling pathways in B-cell chronic lymphocytic leukaemia.Proteomics. 2016 Apr;16(8):1193-203. doi: 10.1002/pmic.201500372. Epub 2016 Apr 4.
• [204] A common V delta 2-D delta 2-D delta 3 T cell receptor gene rearrangement in precursor B acute lymphoblastic leukaemia.Br J Haematol. 1991 Sep;79(1):44-9. doi: 10.1111/j.1365-2141.1991.tb08005.x.
• [205] Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.Oncol Rep. 2012 Aug;28(2):714-20. doi: 10.3892/or.2012.1806. Epub 2012 May 9.
• [206] PRL-2 increases Epo and IL-3 responses in hematopoietic cells.Blood Cells Mol Dis. 2010 Apr 15;44(4):209-14. doi: 10.1016/j.bcmd.2010.02.013. Epub 2010 Mar 11.
• [207] Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.Nat Commun. 2016 Mar 9;7:10933. doi: 10.1038/ncomms10933.
• [208] Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays.Blood. 2007 Feb 1;109(3):1202-10. doi: 10.1182/blood-2006-07-034256. Epub 2006 Oct 19.
• [209] Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase but not SYK or BTK in chronic lymphocytic leukemia cells.J Immunol. 2015 Mar 1;194(5):2439-46. doi: 10.4049/jimmunol.1402304. Epub 2015 Jan 28.
• [210] Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.J Clin Oncol. 2005 May 20;23(15):3433-8. doi: 10.1200/JCO.2005.04.531. Epub 2005 Apr 4.
• [211] L-Selectin Expression is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia.Cytometry B Clin Cytom. 2019 Mar;96(2):149-157. doi: 10.1002/cyto.b.21771. Epub 2019 Feb 6.
• [212] In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.Blood. 2006 Aug 15;108(4):1135-44. doi: 10.1182/blood-2006-01-013003. Epub 2006 Apr 18.
• [213] CpG island methylation patterns in chronic lymphocytic leukemia.Leuk Lymphoma. 2009 Mar;50(3):419-26. doi: 10.1080/10428190902756594.
• [214] Expression of B cell-associated transcription factors in B-cell precursor acute lymphoblastic leukemia cells: association with PU.1 expression, phenotype, and immunogenotype.Int J Hematol. 2000 Jun;71(4):372-8.
• [215] Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. Eur J Nutr. 2017 Apr;56(3):1123-1133.
• [216] STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.Arch Med Sci. 2019 Sep;15(5):1163-1175. doi: 10.5114/aoms.2018.77733. Epub 2018 Aug 23.
• [217] Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.J Clin Endocrinol Metab. 1994 Feb;78(2):398-403. doi: 10.1210/jcem.78.2.8106629.
• [218] STAT6 phosphorylation upregulates microRNA-155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia.Oncol Lett. 2019 Jul;18(1):95-100. doi: 10.3892/ol.2019.10294. Epub 2019 Apr 30.
• [219] Chromosome analyses in chronic lymphocytic leukemia and related B-cell neoplasms.Cancer Genet Cytogenet. 1991 Aug;55(1):49-56. doi: 10.1016/0165-4608(91)90234-l.
• [220] Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors.Blood Cells Mol Dis. 2008 Sep-Oct;41(2):203-9. doi: 10.1016/j.bcmd.2008.05.003. Epub 2008 Jul 14.
• [221] High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.Am J Clin Pathol. 2010 Sep;134(3):472-7. doi: 10.1309/AJCPHMYT93HUIZKW.
• [222] Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.Blood. 2015 Aug 6;126(6):766-78. doi: 10.1182/blood-2014-12-618678. Epub 2015 Jun 3.
• [223] Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses.Leuk Lymphoma. 2011 Jul;52(7):1290-301. doi: 10.3109/10428194.2011.567317.
• [224] NF-B-dependent RANKL expression in a mouse model of immature T-cell leukemia.Biochem Biophys Res Commun. 2019 Mar 5;510(2):272-277. doi: 10.1016/j.bbrc.2019.01.089. Epub 2019 Jan 30.
• [225] TACI expression and signaling in chronic lymphocytic leukemia.J Immunol Res. 2015;2015:478753. doi: 10.1155/2015/478753. Epub 2015 Apr 9.
• [226] Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia.Tumour Biol. 2016 Oct;37(10):13617-13626. doi: 10.1007/s13277-016-5182-z. Epub 2016 Jul 29.
• [227] Anti-BCMA antibodies in the future management of multiple myeloma.Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18.
• [228] PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.Macromol Biosci. 2017 May;17(5). doi: 10.1002/mabi.201600169. Epub 2016 Dec 20.
• [229] RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.Cancer Res. 2013 Jan 15;73(2):683-94. doi: 10.1158/0008-5472.CAN-12-2280. Epub 2012 Nov 8.
• [230] HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.Mol Ther. 2002 Oct;6(4):455-63. doi: 10.1006/mthe.2002.0693.
• [231] Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.Blood. 2005 Mar 15;105(6):2436-42. doi: 10.1182/blood-2004-07-2556. Epub 2004 Nov 9.
• [232] STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.J Immunother Cancer. 2019 Apr 23;7(1):111. doi: 10.1186/s40425-019-0591-3.
• [233] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
• [234] Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.Oncotarget. 2017 May 30;8(22):35508-35522. doi: 10.18632/oncotarget.16348.
• [235] The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.Blood. 2003 Apr 1;101(7):2454-60. doi: 10.1182/blood-2002-07-1984. Epub 2002 Nov 21.
• [236] Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-B to repress autocrine STAT3 activation in chronic lymphocytic leukemia.Blood. 2019 Sep 26;134(13):1084-1094. doi: 10.1182/blood.2019001366. Epub 2019 Aug 13.
• [237] Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.Leuk Lymphoma. 2016 Oct;57(10):2409-16. doi: 10.3109/10428194.2016.1161186. Epub 2016 May 17.
• [238] Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.Anticancer Agents Med Chem. 2020;20(3):325-334. doi: 10.2174/1871520619666191019093558.
• [239] Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.JCI Insight. 2019 Apr 2;5(9):e122627. doi: 10.1172/jci.insight.122627.
• [240] p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from -arrestin at early endosomes.Oncogene. 2018 Mar;37(11):1534-1550. doi: 10.1038/s41388-017-0066-2. Epub 2018 Jan 12.
• [241] CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2019 Mar;96(2):143-148. doi: 10.1002/cyto.b.21722. Epub 2018 Oct 16.
• [242] Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia.Oncotarget. 2018 Sep 4;9(69):33124-33137. doi: 10.18632/oncotarget.26043. eCollection 2018 Sep 4.
• [243] Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies.J Immunol Methods. 2020 Jan;476:112675. doi: 10.1016/j.jim.2019.112675. Epub 2019 Oct 17.
• [244] Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth.Int J Mol Sci. 2019 Jan 12;20(2):292. doi: 10.3390/ijms20020292.
• [245] BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo.Sci Rep. 2019 Jan 24;9(1):701. doi: 10.1038/s41598-018-36853-8.
• [246] PI3K-p110 contributes to antibody responses by macrophages in chronic lymphocytic leukemia.Leukemia. 2020 Feb;34(2):451-461. doi: 10.1038/s41375-019-0556-z. Epub 2019 Aug 28.
• [247] The regulatory capacity of B cells directs the aggressiveness of CLL.Oncoimmunology. 2018 Dec 12;8(3):1554968. doi: 10.1080/2162402X.2018.1554968. eCollection 2019.
• [248] SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.Haematologica. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24.
• [249] Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery.Blood Adv. 2019 Jul 23;3(14):2069-2081. doi: 10.1182/bloodadvances.2019000098.
• [250] Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
• [251] Over-expression of Bcl-2 provides protection in septic mice by a trans effect.J Immunol. 2003 Sep 15;171(6):3136-41. doi: 10.4049/jimmunol.171.6.3136.
• [252] Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.Mod Pathol. 2008 Nov;21(11):1387-93. doi: 10.1038/modpathol.2008.110. Epub 2008 Jul 4.
• [253] Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients.Pathol Oncol Res. 2020 Apr;26(2):743-752. doi: 10.1007/s12253-019-00613-4. Epub 2019 Feb 18.
• [254] Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.Haematologica. 2008 Dec;93(12):1843-51. doi: 10.3324/haematol.13186. Epub 2008 Oct 22.
• [255] Three-year follow-up of treatment-nave and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Blood. 2015 Apr 16;125(16):2497-506. doi: 10.1182/blood-2014-10-606038. Epub 2015 Feb 19.
• [256] Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.Cancer Res. 2016 Mar 15;76(6):1485-1493. doi: 10.1158/0008-5472.CAN-15-1410.
• [257] Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712.
• [258] N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes.Hematol Oncol. 2016 Jun;34(2):79-83. doi: 10.1002/hon.2193. Epub 2015 Feb 17.
• [259] Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia.J Immunol. 2011 Jun 1;186(11):6338-44. doi: 10.4049/jimmunol.0902875. Epub 2011 Apr 27.
• [260] Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients.Hum Mol Genet. 2013 Jun 1;22(11):2273-82. doi: 10.1093/hmg/ddt078. Epub 2013 Feb 14.
• [261] Ecto-5'-nucleotidase in B-cell chronic lymphocytic leukemia.Biomed Pharmacother. 2002 Mar;56(2):100-4. doi: 10.1016/s0753-3322(01)00072-5.
• [262] Assignment of 48 ESTs to chromosome 13 band q14.3 and expression pattern for ESTs located in the core region deleted in B-CLL.Genomics. 1998 Sep 15;52(3):369-73. doi: 10.1006/geno.1998.5464.
• [263] Inactivation of Prostaglandin E(2) as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia.Front Oncol. 2019 Jul 4;9:606. doi: 10.3389/fonc.2019.00606. eCollection 2019.
• [264] Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray.Oncol Lett. 2018 Jan;15(1):361-367. doi: 10.3892/ol.2017.7287. Epub 2017 Oct 30.
• [265] Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.Leukemia. 2017 Dec;31(12):2615-2622. doi: 10.1038/leu.2017.133. Epub 2017 May 3.
• [266] Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.Mol Cell Proteomics. 2018 Apr;17(4):776-791. doi: 10.1074/mcp.RA117.000539. Epub 2018 Jan 24.
• [267] Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.Mol Cancer Res. 2017 May;15(5):610-618. doi: 10.1158/1541-7786.MCR-16-0291. Epub 2017 Jan 27.
• [268] Expression and regulation of CacyBP/SIP in chronic lymphocytic leukemia cell balances of cell proliferation with apoptosis.J Cancer Res Clin Oncol. 2016 Apr;142(4):741-8. doi: 10.1007/s00432-015-2077-0. Epub 2015 Nov 25.
• [269] Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/-catenin pathway.Biochem Biophys Res Commun. 2018 Sep 3;503(1):385-390. doi: 10.1016/j.bbrc.2018.06.045. Epub 2018 Jun 15.
• [270] Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.Mol Med Rep. 2018 Jan;17(1):465-473. doi: 10.3892/mmr.2017.7860. Epub 2017 Oct 24.
• [271] A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.Cell Death Dis. 2016 Jun 2;7(6):e2249. doi: 10.1038/cddis.2016.148.
• [272] Dock10, a novel CZH protein selectively induced by interleukin-4 in human B lymphocytes.Mol Immunol. 2008 Jul;45(12):3411-8. doi: 10.1016/j.molimm.2008.04.003. Epub 2008 May 21.
• [273] Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.Blood. 2018 Jul 12;132(2):170-178. doi: 10.1182/blood-2017-12-819383. Epub 2018 Apr 20.
• [274] Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003.Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2311-2321. doi: 10.1007/s00259-019-04417-1. Epub 2019 Jul 15.
• [275] Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.Leukemia. 2017 Sep;31(9):1882-1893. doi: 10.1038/leu.2016.383. Epub 2016 Dec 26.
• [276] EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.
• [277] Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.Nat Genet. 2013 Aug;45(8):868-76. doi: 10.1038/ng.2652. Epub 2013 Jun 16.
• [278] 1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia.Clin Exp Med. 2019 May;19(2):261-267. doi: 10.1007/s10238-019-00551-0. Epub 2019 Mar 15.
• [279] Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.Cancer Res. 2008 Sep 15;68(18):7512-9. doi: 10.1158/0008-5472.CAN-07-6446.
• [280] Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia.PLoS One. 2017 Jun 30;12(6):e0179883. doi: 10.1371/journal.pone.0179883. eCollection 2017.
• [281] GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.Invest New Drugs. 2018 Oct;36(5):955-960. doi: 10.1007/s10637-018-0613-x. Epub 2018 May 31.
• [282] Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.J Control Release. 2017 Sep 10;261:287-296. doi: 10.1016/j.jconrel.2017.07.010. Epub 2017 Jul 9.
• [283] Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.Clin Cancer Res. 2017 Feb 1;23(3):735-745. doi: 10.1158/1078-0432.CCR-16-0594. Epub 2016 Aug 8.
• [284] Histone H1 quantity determines the efficiency of chromatin condensation in both apoptotic and live cells.Biochem Biophys Res Commun. 2019 Apr 30;512(2):202-207. doi: 10.1016/j.bbrc.2019.03.030. Epub 2019 Mar 14.
• [285] IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.APMIS. 2017 Jun;125(6):511-522. doi: 10.1111/apm.12692. Epub 2017 May 18.
• [286] Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia.J Cell Mol Med. 2018 May;22(5):2846-2855. doi: 10.1111/jcmm.13579. Epub 2018 Mar 7.
• [287] Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival.J Immunol. 2020 Jan 15;204(2):360-374. doi: 10.4049/jimmunol.1900153. Epub 2019 Dec 13.
• [288] Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Tumour Biol. 2010 Jan;31(1):33-45. doi: 10.1007/s13277-009-0005-0. Epub 2009 Dec 18.
• [289] Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.PLoS One. 2018 Feb 12;13(2):e0192839. doi: 10.1371/journal.pone.0192839. eCollection 2018.
• [290] Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.Br J Haematol. 2019 Jun;185(5):852-864. doi: 10.1111/bjh.15877. Epub 2019 Mar 28.
• [291] Lamin B1 regulates somatic mutations and progression of B-cell malignancies.Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14.
• [292] Lipin-1 regulates Bnip3-mediated mitophagy in glycolytic muscle.FASEB J. 2018 Dec;32(12):6796-6807. doi: 10.1096/fj.201800374. Epub 2018 Jun 25.
• [293] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.
• [294] IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.
• [295] Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study.Haematologica. 2018 Nov;103(11):1881-1888. doi: 10.3324/haematol.2018.192526. Epub 2018 Jun 28.
• [296] Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia.Genet Med. 2017 Feb;19(2):182-191. doi: 10.1038/gim.2016.81. Epub 2016 Jul 28.
• [297] MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.J Clin Oncol. 2016 Oct 1;34(28):3451-9. doi: 10.1200/JCO.2016.66.5547. Epub 2016 Aug 9.
• [298] Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control.Sci Rep. 2019 Mar 11;9(1):4155. doi: 10.1038/s41598-019-40697-1.
• [299] Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.Oncol Res Treat. 2019;42(4):202-208. doi: 10.1159/000497208. Epub 2019 Mar 14.
• [300] Combined BTK and PI3K Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.Clin Cancer Res. 2017 Oct 1;23(19):5814-5823. doi: 10.1158/1078-0432.CCR-17-0650. Epub 2017 Jun 23.
• [301] RUNX1-PDCD6 fusion resulting from a novel t(5;21)(p15;q22) chromosome translocation in myelodysplastic syndrome secondary to chronic lymphocytic leukemia.PLoS One. 2018 Apr 19;13(4):e0196181. doi: 10.1371/journal.pone.0196181. eCollection 2018.
• [302] Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.
• [303] Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.Sci Rep. 2017 Sep 25;7(1):12262. doi: 10.1038/s41598-017-12135-7.
• [304] Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.BMC Cancer. 2017 Mar 16;17(1):198. doi: 10.1186/s12885-017-3176-x.
• [305] Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.Expert Opin Ther Targets. 2017 Aug;21(8):767-779. doi: 10.1080/14728222.2017.1349754. Epub 2017 Jul 18.
• [306] A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.Nat Genet. 2008 Oct;40(10):1204-10. doi: 10.1038/ng.219. Epub 2008 Aug 31.
• [307] MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia.Leuk Lymphoma. 2008 Feb;49(2):273-80. doi: 10.1080/10428190701760037.
• [308] Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.Blood Adv. 2018 Jul 10;2(13):1551-1561. doi: 10.1182/bloodadvances.2017014506.
• [309] The Phospholipase C2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.J Biol Chem. 2016 Oct 14;291(42):22136-22148. doi: 10.1074/jbc.M116.746842. Epub 2016 Aug 19.
• [310] Cohesin RAD21 Gene Promoter Methylation in Patients with Chronic Lymphocytic Leukemia.Cytogenet Genome Res. 2018;154(3):126-131. doi: 10.1159/000487868. Epub 2018 Mar 24.
• [311] Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemia.Leuk Lymphoma. 2008 Jan;49(1):130-3. doi: 10.1080/10428190701606800.
• [312] Role of ribosomal protein mutations in tumor development (Review).Int J Oncol. 2016 Apr;48(4):1313-24. doi: 10.3892/ijo.2016.3387. Epub 2016 Feb 9.
• [313] SENP2 exerts an antitumor effect on chronic lymphocytic leukemia cells through the inhibition of the Notch and NFB signaling pathways.Int J Oncol. 2019 Feb;54(2):455-466. doi: 10.3892/ijo.2018.4635. Epub 2018 Nov 14.
• [314] Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.
• [315] The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.Leuk Lymphoma. 2017 Oct;58(10):2419-2425. doi: 10.1080/10428194.2017.1295142. Epub 2017 Feb 28.
• [316] Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.Cancer Immunol Res. 2018 Sep;6(9):1008-1013. doi: 10.1158/2326-6066.CIR-18-0102. Epub 2018 Jul 6.
• [317] Upregulation of SRF Is Associated With Hypoxic Pulmonary Hypertension by Promoting Viability of Smooth Muscle Cells via Increasing Expression of Bcl-2.J Cell Biochem. 2017 Sep;118(9):2731-2738. doi: 10.1002/jcb.25922. Epub 2017 Apr 25.
• [318] Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia.Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1043-9. doi: 10.1158/1055-9965.EPI-15-1329. Epub 2016 May 13.
• [319] Leukemia development initiated by deletion of RBP-J: mouse strain, deletion efficiency and cell of origin.Dis Model Mech. 2018 Dec 18;11(12):dmm036731. doi: 10.1242/dmm.036731.
• [320] Association of TAP1 and TAP2 gene polymorphisms with hematological malignancies.Asian Pac J Cancer Prev. 2013;14(9):5213-7. doi: 10.7314/apjcp.2013.14.9.5213.
• [321] A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia.Leuk Res. 2017 Aug;59:66-74. doi: 10.1016/j.leukres.2017.05.017. Epub 2017 May 29.
• [322] ZO-1 expression shows prognostic value in chronic B cell leukemia.Immunobiology. 2016 Jan;221(1):6-11. doi: 10.1016/j.imbio.2015.08.008. Epub 2015 Aug 17.
• [323] TNR/11q#1 trinucleotide (GCC)n repeat alleles and predisposition to acute and chronic leukemia.Ann Hum Genet. 2004 Jul;68(Pt 4):362-6. doi: 10.1046/j.1529-8817.2004.00101.x.
• [324] Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.Oncotarget. 2017 Apr 11;8(15):25469-25481. doi: 10.18632/oncotarget.16038.
• [325] Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.Nat Genet. 2010 Feb;42(2):132-6. doi: 10.1038/ng.510. Epub 2010 Jan 10.
• [326] A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.Exp Hematol. 2012 Mar;40(3):197-206.e1. doi: 10.1016/j.exphem.2011.11.005. Epub 2011 Nov 23.
• [327] Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1(Suppl 1):S17-24. doi: 10.1016/j.clml.2011.03.031. Epub 2011 May 5.
• [328] Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression.Leuk Res. 2013 Jul;37(7):816-21. doi: 10.1016/j.leukres.2013.04.014. Epub 2013 May 1.
• [329] B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.Blood. 2009 Apr 30;113(18):4188-96. doi: 10.1182/blood-2008-09-176149. Epub 2008 Nov 17.
• [330] The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia.Med Oncol. 2011 Dec;28(4):1542-8. doi: 10.1007/s12032-010-9555-7. Epub 2010 Jun 24.
• [331] The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.Oncotarget. 2015 Dec 1;6(38):40981-97. doi: 10.18632/oncotarget.5715.
• [332] Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens.BMC Cancer. 2015 Oct 16;15:714. doi: 10.1186/s12885-015-1708-9.
• [333] Chronic lymphocytic leukemia in a child: a challenging diagnosis in pediatric oncology practice.Pediatr Blood Cancer. 2014 May;61(5):933-5. doi: 10.1002/pbc.24865. Epub 2013 Nov 19.
• [334] Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.Cancer Biomark. 2011-2012;11(1):15-28. doi: 10.3233/CBM-2012-0259.
• [335] Functional and cancer genomics of ASXL family members.Br J Cancer. 2013 Jul 23;109(2):299-306. doi: 10.1038/bjc.2013.281. Epub 2013 Jun 4.
• [336] GALNT11 as a new molecular marker in chronic lymphocytic leukemia.Gene. 2014 Jan 1;533(1):270-9. doi: 10.1016/j.gene.2013.09.052. Epub 2013 Sep 27.
• [337] Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.Blood. 2013 May 2;121(18):3658-65. doi: 10.1182/blood-2013-01-476606. Epub 2013 Mar 18.
• [338] Bcl6a function is required during optic cup formation to prevent p53-dependent apoptosis and colobomata.Hum Mol Genet. 2013 Sep 1;22(17):3568-82. doi: 10.1093/hmg/ddt211. Epub 2013 May 12.
• [339] CD38 and CD157: a long journey from activation markers to multifunctional molecules.Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):207-17. doi: 10.1002/cyto.b.21092. Epub 2013 Apr 10.
• [340] Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.Clin Cancer Res. 2012 Jul 15;18(14):3791-802. doi: 10.1158/1078-0432.CCR-11-2342. Epub 2012 May 23.
• [341] Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.Leukemia. 2009 Nov;23(11):2018-26. doi: 10.1038/leu.2009.144. Epub 2009 Jul 30.
• [342] IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.PLoS One. 2015 Apr 24;10(4):e0124936. doi: 10.1371/journal.pone.0124936. eCollection 2015.
• [343] Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia.PLoS One. 2015 Mar 20;10(3):e0118905. doi: 10.1371/journal.pone.0118905. eCollection 2015.
• [344] Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies.Int J Oncol. 2014 Apr;44(4):1193-8. doi: 10.3892/ijo.2014.2291. Epub 2014 Feb 5.
• [345] KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia.Epigenetics. 2012 Mar;7(3):211-5. doi: 10.4161/epi.7.3.19222.
• [346] Immunotoxins in cancer therapy: Review and update.Int Rev Immunol. 2017 Jul 4;36(4):207-219. doi: 10.1080/08830185.2017.1284211. Epub 2017 Mar 1.
• [347] The 9p24.3 breakpoint of a constitutional t(6;9)(p12;p24) in a patient with chronic lymphocytic leukemia maps close to the putative promoter region of the DMRT2 gene.Cytogenet Genome Res. 2009;125(2):81-6. doi: 10.1159/000227830. Epub 2009 Aug 31.
• [348] Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.PLoS One. 2014 Jun 27;9(6):e101063. doi: 10.1371/journal.pone.0101063. eCollection 2014.
• [349] Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia.PLoS One. 2013 Oct 14;8(10):e76155. doi: 10.1371/journal.pone.0076155. eCollection 2013.
• [350] Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.Cancer Biol Ther. 2013 Jan;14(1):6-12. doi: 10.4161/cbt.22623. Epub 2012 Oct 31.
• [351] Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.Tumour Biol. 2016 Sep;37(9):11947-11957. doi: 10.1007/s13277-016-5039-5. Epub 2016 Apr 16.
• [352] The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.Invest New Drugs. 2013 Apr;31(2):458-60. doi: 10.1007/s10637-012-9882-y. Epub 2012 Oct 2.
• [353] RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Oncotarget. 2015 Jun 10;6(16):14632-45. doi: 10.18632/oncotarget.4104.
• [354] A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.BMC Cancer. 2010 May 12;10:195. doi: 10.1186/1471-2407-10-195.
• [355] The role of phosphatidylinositol 3-kinase- in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.Blood. 2011 Apr 21;117(16):4323-7. doi: 10.1182/blood-2010-11-315705. Epub 2011 Mar 4.
• [356] Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.FEBS J. 2018 Dec;285(24):4631-4645. doi: 10.1111/febs.14690. Epub 2018 Nov 20.
• [357] Epigenetic alterations in a murine model for chronic lymphocytic leukemia.Cell Cycle. 2009 Nov 15;8(22):3663-7. doi: 10.4161/cc.8.22.9957.
• [358] Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia.Blood. 2009 Mar 26;113(13):3031-9. doi: 10.1182/blood-2008-06-163303. Epub 2009 Jan 28.
• [359] Glutamate dehydrogenase activity in lymphocytes of B-cell chronic lymphocytic leukaemia patients.Clin Biochem. 2009 Nov;42(16-17):1677-84. doi: 10.1016/j.clinbiochem.2009.08.003. Epub 2009 Aug 13.
• [360] Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors.Biochem Pharmacol. 2014 Feb 1;87(3):410-23. doi: 10.1016/j.bcp.2013.11.004. Epub 2013 Nov 22.
• [361] A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.Immunol Res. 2015 Dec;63(1-3):90-100. doi: 10.1007/s12026-015-8688-3.
• [362] Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells.Blood. 2010 Dec 9;116(24):5280-4. doi: 10.1182/blood-2010-02-269829. Epub 2010 Sep 3.
• [363] Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12.Eur J Clin Invest. 2009 Jul;39(7):568-75. doi: 10.1111/j.1365-2362.2009.02146.x. Epub 2009 Apr 30.
• [364] Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.Cancer Cell. 2010 Feb 17;17(2):160-72. doi: 10.1016/j.ccr.2009.12.044.
• [365] Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells.Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):18078-83. doi: 10.1073/pnas.1411390111. Epub 2014 Nov 25.
• [366] BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.J Cell Sci. 2013 May 1;126(Pt 9):1969-80. doi: 10.1242/jcs.118174. Epub 2013 Mar 13.
• [367] Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.J Mol Diagn. 2009 Jan;11(1):25-34. doi: 10.2353/jmoldx.2009.080037. Epub 2008 Dec 12.
• [368] Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.Blood. 2013 Nov 7;122(19):3308-16. doi: 10.1182/blood-2013-05-504597. Epub 2013 Sep 5.
• [369] SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.Haematologica. 2016 Dec;101(12):1553-1562. doi: 10.3324/haematol.2015.139154. Epub 2016 Jul 21.
• [370] LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.Blood. 2011 Apr 14;117(15):4076-84. doi: 10.1182/blood-2010-09-304881. Epub 2011 Feb 10.
• [371] Candidate gene association analysis of acute lymphoblastic leukemia identifies new susceptibility locus at 11p15 (LMO1).Carcinogenesis. 2011 Sep;32(9):1349-53. doi: 10.1093/carcin/bgr091. Epub 2011 May 21.
• [372] Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).PLoS One. 2009 Sep 25;4(9):e7169. doi: 10.1371/journal.pone.0007169.
• [373] A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.Br J Haematol. 2011 Feb;152(3):284-94. doi: 10.1111/j.1365-2141.2010.08482.x. Epub 2010 Dec 1.
• [374] Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.Mol Cancer. 2013 Jun 1;12:50. doi: 10.1186/1476-4598-12-50.
• [375] Identification of MNDA as a new marker for nodal marginal zone lymphoma.Leukemia. 2009 Oct;23(10):1847-57. doi: 10.1038/leu.2009.108. Epub 2009 May 28.
• [376] Dysregulation of TNF-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.Leukemia. 2012 Jun;26(6):1293-300. doi: 10.1038/leu.2011.357. Epub 2011 Dec 13.
• [377] miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.Clin Cancer Res. 2011 May 1;17(9):2712-24. doi: 10.1158/1078-0432.CCR-10-3244. Epub 2011 Mar 2.
• [378] B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18956-60. doi: 10.1073/pnas.1013420107. Epub 2010 Oct 18.
• [379] Protein kinase c--dependent activation of NF-B in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.
• [380] Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.J Leukoc Biol. 2019 Mar;105(3):531-538. doi: 10.1002/JLB.2AB0218-076RR. Epub 2018 Dec 17.
• [381] Lack of association of the NPAS2 gene Ala394Thr polymorphism (rs2305160:G>A) with risk of chronic lymphocytic leukemia.Asian Pac J Cancer Prev. 2014;15(17):7169-74. doi: 10.7314/apjcp.2014.15.17.7169.
• [382] NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function.Cancer Discov. 2014 May;4(5):564-77. doi: 10.1158/2159-8290.CD-13-0419. Epub 2014 Feb 17.
• [383] Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28.
• [384] Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression.Dev Dyn. 2014 Jan;243(1):145-58. doi: 10.1002/dvdy.24056. Epub 2013 Oct 7.
• [385] Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.Leukemia. 2010 Dec;24(12):2063-71. doi: 10.1038/leu.2010.201. Epub 2010 Sep 23.
• [386] A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.PLoS One. 2013 Jun 24;8(6):e67601. doi: 10.1371/journal.pone.0067601. Print 2013.
• [387] Mutated and non-mutated TP53 as targets in the treatment of leukaemia.Br J Haematol. 2008 May;141(4):445-53. doi: 10.1111/j.1365-2141.2008.07046.x. Epub 2008 Mar 12.
• [388] Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males.BMC Med Genomics. 2010 Nov 10;3:53. doi: 10.1186/1755-8794-3-53.
• [389] MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27.Blood. 2010 May 13;115(19):3949-59. doi: 10.1182/blood-2009-11-254656. Epub 2010 Mar 4.
• [390] Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.Sci Rep. 2014 Oct 9;4:6565. doi: 10.1038/srep06565.
• [391] Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.Genes Chromosomes Cancer. 2014 Jul;53(7):612-21. doi: 10.1002/gcc.22171. Epub 2014 Apr 4.
• [392] Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.Epigenetics. 2010 Aug 16;5(6):499-508. doi: 10.4161/epi.5.6.12179. Epub 2010 Aug 16.
• [393] Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies.Fam Cancer. 2014 Sep;13(3):507-11. doi: 10.1007/s10689-014-9725-4.
• [394] Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.Blood. 2009 Apr 2;113(14):3168-71. doi: 10.1182/blood-2008-10-184853. Epub 2008 Dec 2.
• [395] Amplification of B cell receptor-Erk signaling by Rasgrf-1 overexpression in chronic lymphocytic leukemia.Leuk Lymphoma. 2014 Dec;55(12):2907-16. doi: 10.3109/10428194.2014.898759. Epub 2014 Apr 2.
• [396] Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.Biomed Res Int. 2014;2014:423174. doi: 10.1155/2014/423174. Epub 2014 May 5.
• [397] A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1 pathway.Cancer Sci. 2011 Jun;102(6):1208-15. doi: 10.1111/j.1349-7006.2011.01925.x. Epub 2011 May 3.
• [398] 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.Eur J Immunol. 2012 Mar;42(3):737-48. doi: 10.1002/eji.201141920. Epub 2011 Dec 20.
• [399] TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-B pathway in non-small-cell lung carcinoma cells.Gene. 2019 Oct 5;715:144015. doi: 10.1016/j.gene.2019.144015. Epub 2019 Jul 26.
• [400] Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL.Br J Haematol. 2012 Sep;158(5):626-34. doi: 10.1111/j.1365-2141.2012.09222.x. Epub 2012 Jul 6.
• [401] Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.Haematologica. 2011 Nov;96(11):1644-52. doi: 10.3324/haematol.2011.044792. Epub 2011 Jul 12.
• [402] Differential and tumor-specific expression of CD160 in B-cell malignancies.Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.
• [403] IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.Ann Hematol. 2009 Dec;88(12):1215-21. doi: 10.1007/s00277-009-0742-6. Epub 2009 Apr 2.
• [404] Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.Exp Hematol. 2001 Feb;29(2):228-33. doi: 10.1016/s0301-472x(00)00623-8.
• [405] miR-15a and miR-16-1 down-regulation in pituitary adenomas.J Cell Physiol. 2005 Jul;204(1):280-5. doi: 10.1002/jcp.20282.
• [406] Comparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL).Cytometry B Clin Cytom. 2006 Jul 15;70(4):293-301. doi: 10.1002/cyto.b.20133.
• [407] Assignment of the human MAD and MXI1 genes to chromosomes 2p12-p13 and 10q24-q25.Genomics. 1994 Sep 1;23(1):282-5. doi: 10.1006/geno.1994.1496.
• [408] Copper nanoparticle-induced uterine injury in female rats.Environ Toxicol. 2019 Mar;34(3):252-261. doi: 10.1002/tox.22680. Epub 2018 Dec 16.
• [409] Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.Genes Chromosomes Cancer. 2011 Jul;50(7):546-58. doi: 10.1002/gcc.20879. Epub 2011 Apr 15.
• [410] A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.Leukemia. 2010 Nov;24(11):1893-900. doi: 10.1038/leu.2010.191. Epub 2010 Sep 30.
• [411] Wnt5a induces ROR1 to associate with 14-3-3 for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.Leukemia. 2017 Dec;31(12):2608-2614. doi: 10.1038/leu.2017.132. Epub 2017 May 3.
• [412] Genetic variants associated with autoimmunity drive NFB signaling and responses to inflammatory stimuli.Sci Transl Med. 2015 Jun 10;7(291):291ra93. doi: 10.1126/scitranslmed.aaa9223.
• [413] Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability.Front Oncol. 2019 Nov 20;9:1268. doi: 10.3389/fonc.2019.01268. eCollection 2019.
• [414] bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.Blood. 1993 Sep 15;82(6):1820-8.
• [415] Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.Int J Mol Med. 2007 Oct;20(4):461-9.
• [416] A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.Nat Med. 2010 Jun;16(6):671-7. doi: 10.1038/nm.2158. Epub 2010 May 23.
• [417] Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.Int J Mol Sci. 2019 Dec 12;20(24):6277. doi: 10.3390/ijms20246277.
• [418] Association of GRP78, HIF-1 and BAG3 Expression with the Severity of Chronic Lymphocytic Leukemia.Anticancer Agents Med Chem. 2020;20(4):429-436. doi: 10.2174/1871520619666191211101357.
• [419] Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease.Front Cell Neurosci. 2017 Mar 29;11:89. doi: 10.3389/fncel.2017.00089. eCollection 2017.
• [420] Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers.Med Oncol. 2013 Mar;30(1):405. doi: 10.1007/s12032-012-0405-7. Epub 2013 Jan 5.
• [421] Mutations of the BIK gene in human peripheral B-cell lymphomas.Genes Chromosomes Cancer. 2003 Sep;38(1):91-6. doi: 10.1002/gcc.10245.
• [422] Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.Epigenetics. 2011 Mar;6(3):300-6. doi: 10.4161/epi.6.3.14038. Epub 2011 Mar 1.
• [423] Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.Cancer. 2019 Feb 15;125(4):559-574. doi: 10.1002/cncr.31831. Epub 2018 Dec 3.
• [424] Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia.Cancer Res. 2008 Dec 15;68(24):10178-86. doi: 10.1158/0008-5472.CAN-08-2221.
• [425] The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.PLoS One. 2017 Oct 5;12(10):e0185940. doi: 10.1371/journal.pone.0185940. eCollection 2017.
• [426] Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells.Leukemia. 2002 Dec;16(12):2429-37. doi: 10.1038/sj.leu.2402711.
• [427] Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.
• [428] Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.Cancer Immunol Res. 2015 Jul;3(7):815-26. doi: 10.1158/2326-6066.CIR-15-0054. Epub 2015 May 4.
• [429] Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation.Leukemia. 2005 Aug;19(8):1376-83. doi: 10.1038/sj.leu.2403822.
• [430] 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.Leuk Lymphoma. 2006 Feb;47(2):231-44. doi: 10.1080/10428190500254141.
• [431] CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.J Clin Invest. 2018 Dec 3;128(12):5465-5478. doi: 10.1172/JCI96610. Epub 2018 Nov 5.
• [432] Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia.Blood. 2001 Apr 1;97(7):2098-104. doi: 10.1182/blood.v97.7.2098.
• [433] Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia.J Hum Genet. 2006;51(9):832-838. doi: 10.1007/s10038-006-0029-x. Epub 2006 Aug 3.
• [434] Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.PLoS One. 2015 Nov 25;10(11):e0143685. doi: 10.1371/journal.pone.0143685. eCollection 2015.
• [435] IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors.Eur J Immunol. 2006 Jul;36(7):1963-74. doi: 10.1002/eji.200535751.
• [436] A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.Clin Cancer Res. 2016 Sep 1;22(17):4525-35. doi: 10.1158/1078-0432.CCR-15-3103. Epub 2016 Apr 8.
• [437] Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32).Oncogene. 2004 Sep 9;23(41):6991-6. doi: 10.1038/sj.onc.1207934.
• [438] Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.Blood. 1999 Jul 15;94(2):748-53.
• [439] Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.Cell Physiol Biochem. 2018;50(6):2314-2328. doi: 10.1159/000495092. Epub 2018 Nov 13.
• [440] The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.Br J Haematol. 2016 Sep;174(5):767-75. doi: 10.1111/bjh.14132. Epub 2016 May 6.
• [441] Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.Hum Pathol. 2019 Mar;85:251-259. doi: 10.1016/j.humpath.2018.10.038. Epub 2018 Nov 17.
• [442] Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.Eur J Cancer. 2007 May;43(8):1328-35. doi: 10.1016/j.ejca.2007.02.005. Epub 2007 Apr 20.
• [443] Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).Cancer Biol Ther. 2004 Oct;3(10):989-94. doi: 10.4161/cbt.3.10.1137. Epub 2004 Oct 2.
• [444] Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-B signaling.Leukemia. 2018 Jan;32(1):72-82. doi: 10.1038/leu.2017.168. Epub 2017 Jun 1.
• [445] Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-.J Biol Chem. 2016 Oct 14;291(42):22030-22042. doi: 10.1074/jbc.M116.725796. Epub 2016 Sep 2.
• [446] The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.Cancer Res. 2004 Sep 15;64(18):6750-5. doi: 10.1158/0008-5472.CAN-04-1713.
• [447] High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle.Oncotarget. 2014 Jul 15;5(13):4694-708. doi: 10.18632/oncotarget.2100.
• [448] 13q14 deletions in CLL involve cooperating tumor suppressors.Blood. 2010 May 13;115(19):3916-22. doi: 10.1182/blood-2009-10-249367. Epub 2010 Jan 13.
• [449] Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation.Oncol Rep. 2007 Aug;18(2):417-23.
• [450] Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.J Cell Mol Med. 2020 Jan;24(2):1650-1657. doi: 10.1111/jcmm.14857. Epub 2019 Dec 10.
• [451] Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia.Leuk Res. 2005 Jan;29(1):59-61. doi: 10.1016/j.leukres.2004.05.022.
• [452] ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.Blood. 2003 Jun 15;101(12):4944-51. doi: 10.1182/blood-2002-10-3306. Epub 2003 Feb 20.
• [453] DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl Nuclear Power Plant accident.J Radiat Res. 2012;53(3):497-503. doi: 10.1269/jrr.11093.
• [454] Berberine reinforces Sertoli cells niche and accelerates spermatogonial stem cells renewal in experimentally-induced varicocele condition in rats.Phytomedicine. 2018 Feb 1;40:68-78. doi: 10.1016/j.phymed.2017.12.036. Epub 2018 Jan 2.
• [455] Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.EMBO J. 2017 Mar 15;36(6):718-735. doi: 10.15252/embj.201695495. Epub 2017 Feb 20.
• [456] Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. doi: 10.1073/pnas.022604399. Epub 2002 Mar 12.
• [457] Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.Neoplasma. 2006;53(3):219-25.
• [458] A new monoclonal antibody which binds to the cytoplasm of large cell lymphomas.Hematol Oncol. 1992 Mar-Apr;10(2):95-104. doi: 10.1002/hon.2900100205.
• [459] Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemiapatients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.Oncol Rep. 2015 Sep;34(3):1269-78. doi: 10.3892/or.2015.4088. Epub 2015 Jun 26.
• [460] Chimeric antigen receptor T cells targeting Fc receptor selectively eliminate CLL cells while sparing healthy B cells.Blood. 2016 Sep 29;128(13):1711-22. doi: 10.1182/blood-2016-01-692046. Epub 2016 Aug 17.
• [461] Evaluation of CD307a expression patterns during normal B-cell maturation and in B-cell malignancies by flow cytometry.Cytometry B Clin Cytom. 2018 Jul;94(4):588-595. doi: 10.1002/cyto.b.21631. Epub 2018 Mar 9.
• [462] FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.Eur J Haematol. 2009 Dec 1;83(6):541-9. doi: 10.1111/j.1600-0609.2009.01328.x. Epub 2009 Aug 4.
• [463] Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia.Immunol Lett. 2011 Jan 30;134(2):137-44. doi: 10.1016/j.imlet.2010.09.017. Epub 2010 Oct 13.
• [464] Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia.Int J Cancer. 2008 Nov 1;123(9):2113-9. doi: 10.1002/ijc.23751.
• [465] In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by 41 cytoplasmic-binding proteins.Leukemia. 2016 Apr;30(4):861-72. doi: 10.1038/leu.2015.332. Epub 2015 Dec 10.
• [466] Characterization of sunburn cells after exposure to ultraviolet light.Photodermatol Photoimmunol Photomed. 1995 Aug;11(4):149-54. doi: 10.1111/j.1600-0781.1995.tb00157.x.
• [467] CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia.Cancer Res. 2006 Jan 15;66(2):653-8. doi: 10.1158/0008-5472.CAN-05-3712.
• [468] Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23. doi: 10.1073/pnas.0308648100. Epub 2004 Feb 18.
• [469] miR in CLL: more than mere markers of prognosis?.Blood. 2014 Jul 3;124(1):2-4. doi: 10.1182/blood-2014-05-574152.
• [470] Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis.Curr Med Chem. 2020;27(2):282-297. doi: 10.2174/0929867326666190911114842.
• [471] CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.Int J Lab Hematol. 2017 Oct;39(5):552-556. doi: 10.1111/ijlh.12695. Epub 2017 Jun 12.
• [472] The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia.Leuk Lymphoma. 2003 Oct;44(10):1739-43. doi: 10.1080/1042819031000111017.
• [473] Grb7 expression and cellular migration in chronic lymphocytic leukemia: a comparative study of early and advanced stage disease.Leukemia. 2004 Dec;18(12):1948-50. doi: 10.1038/sj.leu.2403512.
• [474] Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.
• [475] High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients.Leuk Res. 2012 Jul;36(7):876-80. doi: 10.1016/j.leukres.2012.01.017. Epub 2012 Feb 12.
• [476] Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.Blood. 2014 Oct 23;124(17):2657-65. doi: 10.1182/blood-2014-02-558767. Epub 2014 Sep 17.
• [477] Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.Leukemia. 2010 Mar;24(3):563-72. doi: 10.1038/leu.2009.281. Epub 2010 Jan 14.
• [478] Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL.Leukemia. 2006 Jul;20(7):1326-9. doi: 10.1038/sj.leu.2404254. Epub 2006 May 11.
• [479] Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.Cell. 2007 Jun 1;129(5):879-90. doi: 10.1016/j.cell.2007.03.043.
• [480] Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia.Blood. 2009 Jan 8;113(2):403-11. doi: 10.1182/blood-2008-07-166868. Epub 2008 Oct 23.
• [481] Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer.J Immunother. 2002 Jan-Feb;25(1):36-45. doi: 10.1097/00002371-200201000-00004.
• [482] Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia.Blood. 1994 Dec 15;84(12):4249-56.
• [483] IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells.Tumour Biol. 2016 Oct;37(10):13927-13939. doi: 10.1007/s13277-016-5283-8. Epub 2016 Aug 3.
• [484] JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.Int J Hematol. 2015 Jul;102(1):76-85. doi: 10.1007/s12185-015-1797-x. Epub 2015 May 5.
• [485] Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25).Blood. 1993 Jul 15;82(2):528-35.
• [486] Prognostic value of the cancer oncogene Kelch-like 6 in gastric cancer.Br J Surg. 2017 Dec;104(13):1847-1856. doi: 10.1002/bjs.10628. Epub 2017 Oct 17.
• [487] 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.Eur J Haematol. 2004 Apr;72(4):259-63. doi: 10.1111/j.0902-4441.2003.00210.x.
• [488] PHA/IL2: an efficient mitogen cocktail for cytogenetic studies of non-Hodgkin lymphoma and chronic lymphocytic leukemia.Cancer Genet Cytogenet. 1999 Mar;109(2):134-7. doi: 10.1016/s0165-4608(98)00150-2.
• [489] DNA repair enzyme expression in chronic lymphocytic leukemia vis--vis nitrogen mustard drug resistance.Cancer Lett. 1995 Apr 14;90(2):139-48. doi: 10.1016/0304-3835(95)03696-t.
• [490] A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.Blood. 2018 Nov 1;132(18):1911-1921. doi: 10.1182/blood-2018-04-843763. Epub 2018 Aug 27.
• [491] Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.Am J Surg Pathol. 2001 Oct;25(10):1268-76. doi: 10.1097/00000478-200110000-00007.
• [492] Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia.Leuk Lymphoma. 1999 Feb;32(5-6):561-9. doi: 10.3109/10428199909058414.
• [493] Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.Blood. 1991 Jul 1;78(1):180-91.
• [494] High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.
• [495] ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5295-304. doi: 10.1158/1078-0432.CCR-07-0283.
• [496] Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.J Hematol Oncol. 2015 Mar 4;8:20. doi: 10.1186/s13045-015-0116-6.
• [497] Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.Int J Cancer. 2007 Mar 15;120(6):1215-22. doi: 10.1002/ijc.22495.
• [498] Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3.Genomics. 1997 Dec 1;46(2):183-90. doi: 10.1006/geno.1997.5008.
• [499] Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.Int J Cancer. 2007 Nov 1;121(9):1984-1993. doi: 10.1002/ijc.22929.
• [500] Proenkephalin A-like mRNA in human leukemia leukocytes and CNS-tissues.Life Sci. 1986 Dec 8;39(23):2237-41. doi: 10.1016/0024-3205(86)90402-9.
• [501] Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia.Mol Biol Rep. 2014 Jan;41(1):95-103. doi: 10.1007/s11033-013-2841-7. Epub 2013 Nov 5.
• [502] Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.Oncotarget. 2015 Dec 29;6(42):44422-36. doi: 10.18632/oncotarget.6251.
• [503] Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAs.Leuk Lymphoma. 2010 Aug;51(8):1379-81. doi: 10.3109/10428194.2010.496016.
• [504] CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes.Blood. 2003 Mar 1;101(5):1962-9. doi: 10.1182/blood-2002-05-1339. Epub 2002 Oct 24.
• [505] Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers.Environ Health. 2018 May 2;17(1):43. doi: 10.1186/s12940-018-0387-9.
• [506] Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia.Genes Chromosomes Cancer. 2005 May;43(1):1-10. doi: 10.1002/gcc.20159.
• [507] Identification of progression markers in B-CLL by gene expression profiling.Exp Hematol. 2005 Aug;33(8):883-93. doi: 10.1016/j.exphem.2005.05.007.
• [508] Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.BMC Cancer. 2019 Jan 17;19(1):81. doi: 10.1186/s12885-019-5276-2.
• [509] Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.Leukemia. 2019 May;33(5):1148-1160. doi: 10.1038/s41375-018-0288-5. Epub 2018 Oct 23.
• [510] MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71.
• [511] The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.Oncogene. 2017 Jun 29;36(26):3686-3694. doi: 10.1038/onc.2016.523. Epub 2017 Feb 6.
• [512] The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia.Clin Cancer Res. 2011 Nov 1;17(21):6778-90. doi: 10.1158/1078-0432.CCR-11-0785. Epub 2011 Sep 2.
• [513] Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation.Leukemia. 2006 Jun;20(6):1089-95. doi: 10.1038/sj.leu.2404183.
• [514] Ribosomal Lesions Promote Oncogenic Mutagenesis.Cancer Res. 2019 Jan 15;79(2):320-327. doi: 10.1158/0008-5472.CAN-18-1987. Epub 2018 Nov 27.
• [515] Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.Int J Oncol. 2012 Jan;40(1):269-76. doi: 10.3892/ijo.2011.1206. Epub 2011 Sep 22.
• [516] The missing link: allostery and catalysis in the anti-viral protein SAMHD1.Biochem Soc Trans. 2019 Aug 30;47(4):1013-1027. doi: 10.1042/BST20180348. Epub 2019 Jul 11.
• [517] SEMG-1 expression in early stage chronic lymphocytic leukemia.Cytotherapy. 2009;11(2):238-44. doi: 10.1080/14653240802716608.
• [518] Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28.
• [519] Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia.Cancer Res. 2001 Apr 1;61(7):2870-7.
• [520] Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.Blood. 2008 May 15;111(10):5101-8. doi: 10.1182/blood-2007-12-130229. Epub 2008 Mar 7.
• [521] The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.Cancer Genet Cytogenet. 2006 Jun;167(2):145-9. doi: 10.1016/j.cancergencyto.2005.11.019.
• [522] Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.Leuk Lymphoma. 2015 May;56(5):1425-31. doi: 10.3109/10428194.2014.953147. Epub 2014 Oct 7.
• [523] Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.Blood. 2003 Feb 1;101(3):955-60. doi: 10.1182/blood-2002-06-1930. Epub 2002 Aug 22.
• [524] RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia.Cancer Genet Cytogenet. 2003 Oct 1;146(1):48-57. doi: 10.1016/s0165-4608(03)00126-2.
• [525] Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.Leukemia. 2007 Sep;21(9):1984-91. doi: 10.1038/sj.leu.2404831. Epub 2007 Jul 5.
• [526] Investigation of copy-number variations of C8orf4 in hematological malignancies.Med Oncol. 2011 Dec;28 Suppl 1:S647-52. doi: 10.1007/s12032-010-9698-6. Epub 2010 Sep 29.
• [527] Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia.Med Oncol. 1999 Jul;16(2):110-8. doi: 10.1007/BF02785844.
• [528] Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma.Blood. 2002 Aug 15;100(4):1425-9.
• [529] TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.Leuk Res. 2016 Nov;50:72-77. doi: 10.1016/j.leukres.2016.09.013. Epub 2016 Sep 15.
• [530] Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.Mol Cell Proteomics. 2003 Dec;2(12):1331-41. doi: 10.1074/mcp.M300055-MCP200. Epub 2003 Oct 13.
• [531] Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.Leukemia. 2001 Dec;15(12):1868-77. doi: 10.1038/sj.leu.2402287.
• [532] Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.J Cell Physiol. 2006 Apr;207(1):158-64. doi: 10.1002/jcp.20547.
• [533] Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph.Haematologica. 2011 Feb;96(2):323-7. doi: 10.3324/haematol.2010.031161. Epub 2010 Nov 3.
• [534] Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.Blood. 2002 Nov 15;100(10):3749-56. doi: 10.1182/blood.V100.10.3749.
• [535] TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.J Immunol. 2012 Jul 15;189(2):1053-61. doi: 10.4049/jimmunol.1200814. Epub 2012 Jun 18.
• [536] BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.Pathol Oncol Res. 2019 Apr;25(2):541-548. doi: 10.1007/s12253-018-0476-7. Epub 2018 Oct 25.
• [537] Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.J Oncol Pharm Pract. 2020 Mar;26(2):478-480. doi: 10.1177/1078155219852146. Epub 2019 May 29.
• [538] Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.Cancer Immunol Immunother. 2019 Apr;68(4):587-598. doi: 10.1007/s00262-019-02304-0. Epub 2019 Feb 6.